<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput. Biol</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6615642</article-id><article-id pub-id-type="pmid">31242175</article-id><article-id pub-id-type="publisher-id">PCOMPBIOL-D-18-01750</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1007023</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>Forms of DNA</subject><subj-group><subject>Mitochondrial DNA</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>Forms of DNA</subject><subj-group><subject>Mitochondrial DNA</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Heredity</subject><subj-group><subject>Heteroplasmy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Bioenergetics</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Structures and Organelles</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Plant Biochemistry</subject><subj-group><subject>Plant Energy Production</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Plant Science</subject><subj-group><subject>Plant Biochemistry</subject><subj-group><subject>Plant Energy Production</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Bioengineering</subject><subj-group><subject>Synthetic Bioengineering</subject><subj-group><subject>Genome Engineering</subject><subj-group><subject>Synthetic Genome Editing</subject><subj-group><subject>Zinc Finger Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Bioengineering</subject><subj-group><subject>Synthetic Bioengineering</subject><subj-group><subject>Genome Engineering</subject><subj-group><subject>Synthetic Genome Editing</subject><subj-group><subject>Zinc Finger Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Synthetic Biology</subject><subj-group><subject>Synthetic Bioengineering</subject><subj-group><subject>Genome Engineering</subject><subj-group><subject>Synthetic Genome Editing</subject><subj-group><subject>Zinc Finger Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Synthetic Biology</subject><subj-group><subject>Synthetic Bioengineering</subject><subj-group><subject>Genome Engineering</subject><subj-group><subject>Synthetic Genome Editing</subject><subj-group><subject>Zinc Finger Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Synthetic Biology</subject><subj-group><subject>Synthetic Genomics</subject><subj-group><subject>Synthetic Genome Editing</subject><subj-group><subject>Zinc Finger Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Synthetic Biology</subject><subj-group><subject>Synthetic Genomics</subject><subj-group><subject>Synthetic Genome Editing</subject><subj-group><subject>Zinc Finger Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>DNA-binding proteins</subject><subj-group><subject>Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Hydrolases</subject><subj-group><subject>Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Hydrolases</subject><subj-group><subject>Nucleases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Genetics</subject><subj-group><subject>Gene Therapy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Gene Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Gene Therapy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Control Engineering</subject><subj-group><subject>Control Theory</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Computer and Information Sciences</subject><subj-group><subject>Systems Science</subject><subj-group><subject>Control Theory</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Systems Science</subject><subj-group><subject>Control Theory</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Energetic costs of cellular and therapeutic control of stochastic mitochondrial DNA populations</article-title><alt-title alt-title-type="running-head">Energetic costs and control of mitochondrial DNA populations</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hoitzing</surname><given-names>Hanne</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1968-1726</contrib-id><name><surname>Gammage</surname><given-names>Payam A.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haute</surname><given-names>Lindsey Van</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8242-1420</contrib-id><name><surname>Minczuk</surname><given-names>Michal</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8559-3519</contrib-id><name><surname>Johnston</surname><given-names>Iain G.</given-names></name><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4083-972X</contrib-id><name><surname>Jones</surname><given-names>Nick S.</given-names></name><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Mathematics, Imperial College London, London, SW7 2AZ, United Kingdom</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, United Kingdom</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>CRUK Beatson Institute for Cancer Research, Glasgow, United Kingdom</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Faculty of Mathematics and Natural Sciences, University of Bergen, Bergen, Norway</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Alan Turing Institute, London, United Kingdom</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Beard</surname><given-names>Daniel A</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Michigan, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>iain.johnston@uib.no</email> (IGJ); <email>nick.jones@imperial.ac.uk</email> (NSJ)</corresp></author-notes><pub-date pub-type="collection"><month>6</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>6</month><year>2019</year></pub-date><volume>15</volume><issue>6</issue><elocation-id>e1007023</elocation-id><history><date date-type="received"><day>13</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Hoitzing et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Hoitzing et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pcbi.1007023.pdf"/><abstract><p>The dynamics of the cellular proportion of mutant mtDNA molecules is crucial for mitochondrial diseases. Cellular populations of mitochondria are under homeostatic control, but the details of the control mechanisms involved remain elusive. Here, we use stochastic modelling to derive general results for the impact of cellular control on mtDNA populations, the cost to the cell of different mtDNA states, and the optimisation of therapeutic control of mtDNA populations. This formalism yields a wealth of biological results, including that an increasing mtDNA variance can increase the energetic cost of maintaining a tissue, that intermediate levels of heteroplasmy can be more detrimental than homoplasmy even for a dysfunctional mutant, that heteroplasmy distribution (not mean alone) is crucial for the success of gene therapies, and that long-term rather than short intense gene therapies are more likely to beneficially impact mtDNA populations.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Mitochondria, best known for their role in energy production, are crucial to the survival of most of our cells. To respond to energetic demands and mitigate against mutational damage, cells control the mitochondrial populations within them. However, the character of these control mechanisms remains open. As experimental elucidation of these mechanisms is challenging, theoretical approaches can help us understand the general principles of cellular control of mitochondria in physiology and disease. Here, we use stochastic modelling to compare control strategies by studying their impact on the dynamics of mitochondrial DNA (mtDNA) populations as well as their energetic burden to the cell. We identify optimal strategies for the cell to control against mtDNA damage and preserve energy production and use this theory to explore the action of recently developed mitochondrial gene therapies, which reduce the fraction of mutant mtDNA molecules inside cells. We show how treatment efficiency may depend on pre-treatment distributions of mutant and wildtype mtDNA molecules: treatments are less effective for tissues consisting of cells with highly varying mutant levels, and long-term, rather than short intense, gene therapies should be favoured.</p></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="27"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2019-07-09</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Most human cells contain 100-10,000 copies of mitochondrial DNA (mtDNA) which are situated inside the mitochondria. The proteins encoded by mtDNA are crucial for mitochondrial functionality, and mutations in mtDNA can cause devastating diseases [<xref rid="pcbi.1007023.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pcbi.1007023.ref006" ref-type="bibr">6</xref>]. Heteroplasmy, the proportion of mutant mtDNA molecules in a cell, typically has to pass a certain threshold (&#x0223c; 60-95%) before any biochemical defects can be observed [<xref rid="pcbi.1007023.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pcbi.1007023.ref014" ref-type="bibr">14</xref>]. The existence of thresholds at which mutant loads begin to have an effect has profound implications for our understanding of disease onset, drawing attention to the variance dynamics of the mutant fraction in cellular populations. As this variance increases more cells can be above threshold, and thus show pathology, even if average mutant load is unchanged.</p><p>Mitochondrial biogenesis and maintenance require cellular resources, and mitochondria are key sources of ATP and play other important metabolic roles. The particular &#x02018;effective cost&#x02019; that cellular control of mitochondria acts to minimise remains poorly understood: for example, both decreases [<xref rid="pcbi.1007023.ref015" ref-type="bibr">15</xref>] and increases [<xref rid="pcbi.1007023.ref015" ref-type="bibr">15</xref>, <xref rid="pcbi.1007023.ref016" ref-type="bibr">16</xref>] in wildtype copy numbers have been observed for different mutations as the mutant load increases. Some studies suggest that mtDNA density is controlled [<xref rid="pcbi.1007023.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pcbi.1007023.ref019" ref-type="bibr">19</xref>], others that total mtDNA mass [<xref rid="pcbi.1007023.ref020" ref-type="bibr">20</xref>, <xref rid="pcbi.1007023.ref021" ref-type="bibr">21</xref>], or mtDNA transcription rate [<xref rid="pcbi.1007023.ref022" ref-type="bibr">22</xref>] is controlled. Understanding mtDNA population dynamics inside cells, and how these populations react to clinical interventions, is crucial in understanding diseases [<xref rid="pcbi.1007023.ref023" ref-type="bibr">23</xref>, <xref rid="pcbi.1007023.ref024" ref-type="bibr">24</xref>]. However, experimental tracking of mtDNA populations over time is challenging, necessitating predictive mathematical modelling to provide a quantitative understanding.</p><p>In parallel with efforts to elucidate cell physiological control, protein engineering methods to artificially control mtDNA heteroplasmy are making fast progress. Two recently developed methods for cleaving DNA at specific sites involve zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) [<xref rid="pcbi.1007023.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pcbi.1007023.ref031" ref-type="bibr">31</xref>], which have been re-engineered to specifically cleave mutant mtDNA [<xref rid="pcbi.1007023.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. MitoTALENs have been successfully used to reduce mutant loads in cells containing disease-related mutations, but elimination of the target mutant mtDNA was not complete [<xref rid="pcbi.1007023.ref032" ref-type="bibr">32</xref>, <xref rid="pcbi.1007023.ref037" ref-type="bibr">37</xref>]. Similarly, treating cells multiple times with mtZFNs led to near-complete elimination of mutant mtDNAs [<xref rid="pcbi.1007023.ref035" ref-type="bibr">35</xref>, <xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. Quantitative theory for these therapeutic technologies has not yet been developed, leaving open questions about how these tools can be optimally deployed.</p><p>In this paper, we develop theory from bottom-up bioenergetic principles which allows us to study the effects of distinct cellular mtDNA control strategies, to analyse the bioenergetic cost of different mtDNA states, and to combine mtDNA control and energy-based cost to identify optimal control strategies for the cell. Finally, we construct a model for therapeutic mtDNA control using recent experimental data [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>] and highlight challenges linked to heteroplasmy variance.</p></sec><sec sec-type="results" id="sec002"><title>Results</title><sec id="sec003"><title>Control: General insights on the role of feedback control</title><p>We employ a linear form of mtDNA feedback control and assume each mtDNA molecule replicates and degrades according to Poisson processes with rates &#x003bb; and <italic>&#x003bc;</italic>, respectively. Because control of biogenesis or autophagy yield similar behaviours [<xref rid="pcbi.1007023.ref038" ref-type="bibr">38</xref>], we assume that the degradation rate <italic>&#x003bc;</italic> is constant and that feedback control is manifest through the replication rate &#x003bb;(<italic>w</italic>, <italic>m</italic>), where <italic>w</italic> and <italic>m</italic> denote the number of mutant and wildtype mtDNA molecules in the cell. To connect with experiments, we use <italic>&#x003bc;</italic> &#x02248; 0.07 day<sup>&#x02212;1</sup> corresponding to a half-life of about 10 days [<xref rid="pcbi.1007023.ref039" ref-type="bibr">39</xref>]. We only model post-mitotic cells, though our analysis can be extended to include cell divisions.</p><p>Specifically, we use a birth rate of the form:
<disp-formula id="pcbi.1007023.e001"><alternatives><graphic xlink:href="pcbi.1007023.e001.jpg" id="pcbi.1007023.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mo>&#x003bb;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b4;</mml:mi><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic>c</italic><sub>1</sub> &#x0003e; 0, <italic>w</italic><sub><italic>opt</italic></sub> &#x0003e; 0 and <italic>&#x003b4;</italic> are constants, with <italic>w</italic><sub><italic>opt</italic></sub> denoting the steady state value towards which the effective population, here defined as <italic>w</italic> + <italic>&#x003b4;m</italic>, is controlled. The magnitude of <italic>c</italic><sub>1</sub> determines how tightly the population is controlled. We use the term &#x02018;mitochondrial sensing&#x02019; to describe how the cell might sense the mitochondrial population that is present. &#x02018;Mutant sensing&#x02019; then refers to how strongly mutants are sensed relatively to wildtypes, which is encoded in the parameter <italic>&#x003b4;</italic>. When steady state is reached (i.e. <italic>w</italic> + <italic>&#x003b4;m</italic> = <italic>w</italic><sub><italic>opt</italic></sub>), replication and degradation rates are equal. In the absence of mutants, the resulting wildtype steady state is assumed to be optimal. We note that assuming the existence of <italic>w</italic><sub><italic>opt</italic></sub> does not imply a control based on copy number. Other quantities related to mitochondria may be controlled instead, such as total mitochondrial mass or ATP production, their desired values being reached at an effective population size of <italic>w</italic><sub><italic>opt</italic></sub>. Thus, we define &#x02018;mitochondrial sensing&#x02019; to refer to a wide range of mechanisms available to the cell to infer properties of its mitochondrial population, which can then be used to decide on a control action.</p><p>The deterministic dynamics resulting from this control are described in <xref ref-type="disp-formula" rid="pcbi.1007023.e029">Eq (4)</xref>. We do not include the possibility of <italic>de novo</italic> mutations but our approach can straightforwardly describe the subsequent behaviour if new mutations arise. Our linear model shares features with the &#x02018;relaxed replication model&#x02019; [<xref rid="pcbi.1007023.ref040" ref-type="bibr">40</xref>, <xref rid="pcbi.1007023.ref041" ref-type="bibr">41</xref>] (<xref ref-type="disp-formula" rid="pcbi.1007023.e030">Eq (5)</xref>), though is written in a simpler form. The relaxed replication model has been used in a variety of other models [<xref rid="pcbi.1007023.ref042" ref-type="bibr">42</xref>, <xref rid="pcbi.1007023.ref043" ref-type="bibr">43</xref>] and has obtained experimental support [<xref rid="pcbi.1007023.ref015" ref-type="bibr">15</xref>].</p><p>We will first investigate properties of more general control strategies, after which we return to our linear control and discuss parameterisations that optimise the energy status of the cell. Finally, we use the linear control to fit recent experimental data involving treatment of heteroplasmic cells with mtZFNs.</p><sec id="sec004"><title>A wide range of control strategies induces similar mtDNA behaviour and admits quantitative analysis</title><p>Many possible control strategies can be parameterised to give rise to nearly identical means and variances for wildtype, mutant, and heteroplasmy dynamics up to long times (e.g. a human life-time) (<xref ref-type="fig" rid="pcbi.1007023.g001">Fig 1A, 1B and 1C</xref>, <xref ref-type="supplementary-material" rid="pcbi.1007023.s001">S1B, S1C and S1D Fig</xref>). This is especially true when mtDNA copy numbers fluctuate around their steady state values, in which case a linear control forms a good first order approximation to the complex &#x02018;true&#x02019; control function. In this case, it is not the manner in which the controlled quantity is being controlled, but <bold>which</bold> quantity is controlled that is the most important. For example, the extent to which mutants and wildtypes contribute to the replication feedback function (determined by <italic>&#x003b4;</italic>) determines how their relative means and variances evolve (<xref ref-type="fig" rid="pcbi.1007023.g001">Fig 1D</xref>), and contains more information on the dynamics than the functional form of &#x003bb;(<italic>w</italic>, <italic>m</italic>) for fixed <italic>&#x003b4;</italic> (e.g. whether &#x003bb;(<italic>w</italic>, <italic>m</italic>) is linear or quadratic).</p><fig id="pcbi.1007023.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.g001</object-id><label>Fig 1</label><caption><p><bold>A-C: A wide range of cellular control strategies can yield similar dynamics</bold>. Stochastic simulations were used to compare three structurally distinct cellular controls (see legend), each reflecting a different function of the underlying sensed quantity <italic>w</italic> + <italic>&#x003b4;m</italic> with <italic>&#x003b4;</italic> = 0.5. All controls are set to have the same wildtype mean and variance in the absence of mutants (section 2 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). No explicit selection for either mtDNA species is used. Figure (C) illustrates the difference between cellular mean and tissue homogenate heteroplasmy. <bold>D: Control tradeoffs are required when multiple species are present</bold>. The more strongly one species is controlled, the more control is lost over the other. Changes in variances between cells as described by the linear noise approximation (section 1 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>) are shown (intermediate times). For long times, fixation occurs and the variance of the surviving species saturates. In the most-right figure we depicted the case in which mutants contribute less to the control than wildtypes (<italic>&#x003b4;</italic> &#x0003c; 1).</p></caption><graphic xlink:href="pcbi.1007023.g001"/></fig><p>We stress the difference between two types of average heteroplasmy, as was also stressed in Ref. [<xref rid="pcbi.1007023.ref041" ref-type="bibr">41</xref>]: the individual cellular mean heteroplasmy <inline-formula id="pcbi.1007023.e002"><alternatives><graphic xlink:href="pcbi.1007023.e002.jpg" id="pcbi.1007023.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msub><mml:mrow><mml:mo>&#x02329;</mml:mo><mml:mi>h</mml:mi><mml:mo>&#x0232a;</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>n</mml:mi><mml:mtext>cells</mml:mtext></mml:msub></mml:mfrac><mml:mstyle displaystyle="true"><mml:munder><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mtext>cells</mml:mtext><mml:mspace width="4.pt"/><mml:mtext>i</mml:mtext></mml:mrow></mml:munder></mml:mstyle><mml:mfrac><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula> (with <italic>n</italic><sub><italic>cells</italic></sub> the number of cells in the tissue) and the tissue homogenate heteroplasmy <inline-formula id="pcbi.1007023.e003"><alternatives><graphic xlink:href="pcbi.1007023.e003.jpg" id="pcbi.1007023.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mrow><mml:msub><mml:mrow><mml:mo>&#x02329;</mml:mo><mml:mi>h</mml:mi><mml:mo>&#x0232a;</mml:mo></mml:mrow><mml:mrow><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mtext>cells</mml:mtext><mml:mspace width="4.pt"/><mml:mtext>i</mml:mtext></mml:mrow></mml:munder></mml:mstyle><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mtext>cells</mml:mtext><mml:mspace width="4.pt"/><mml:mtext>i</mml:mtext></mml:mrow></mml:munder></mml:mstyle><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. This difference is clearly seen in <xref ref-type="fig" rid="pcbi.1007023.g001">Fig 1C</xref>. When no explicit selection is present for either mtDNA species, mean cellular heteroplasmy remains constant at its initial value <italic>m</italic><sub>0</sub>/(<italic>m</italic><sub>0</sub> + <italic>w</italic><sub>0</sub>), where <italic>w</italic><sub>0</sub> and <italic>m</italic><sub>0</sub> denote the initial wildtype and mutant copy numbers, respectively. The homogenate heteroplasmy at long times is given by <italic>m</italic><sub>0</sub>/(<italic>m</italic><sub>0</sub> + <italic>&#x003b4;w</italic><sub>0</sub>) (section 2.2 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). It is clear that when mutants contribute little to the feedback control (small <italic>&#x003b4;</italic>), tissue homogenate heteroplasmy can reach high values, and even approach &#x02329;<italic>h</italic>&#x0232a;<sub><italic>homog</italic></sub> = 1, without explicit selection. A tissue can thus appear, when studying the homogenate heteroplasmy, to show selection for one type of mtDNA over another, whereas in fact mean cellular heteroplasmy is unaltered and mutant and wildtypes have identical proliferation rates.</p></sec><sec id="sec005"><title>Nonlinear cost functions predict changes in tissue maintenance</title><p>The birth-death model used to describe mtDNA dynamics can be written as a master equation (<xref ref-type="sec" rid="sec016">Methods</xref>, section 1 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). <xref ref-type="supplementary-material" rid="pcbi.1007023.s012">S1 Table</xref> shows the first order solution of the system size expansion, an approximation method to master equations, which is known as the linear noise approximation (LNA). Applying this approximation to a general form of mtDNA control (section 1 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>), we find that i) if only one species is controlled, the variance of this species quickly reaches a constant value (see also [<xref rid="pcbi.1007023.ref038" ref-type="bibr">38</xref>]), ii) when both species are controlled with equal strength their variances increase at identical rates, iii) in general the more tightly controlled species has a more slowly increasing variance, and iv) the rate of increase of heteroplasmy variance depends, to first order, only on mtDNA copy number and turnover (as found in [<xref rid="pcbi.1007023.ref038" ref-type="bibr">38</xref>]) (<xref ref-type="fig" rid="pcbi.1007023.g001">Fig 1</xref>, <xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e004"><alternatives><graphic xlink:href="pcbi.1007023.e004.jpg" id="pcbi.1007023.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mi mathvariant="double-struck">I</mml:mi></mml:math></alternatives></inline-formula>)). Eventually, all variances reach a constant value due to fixation.</p><table-wrap id="pcbi.1007023.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.t001</object-id><label>Table 1</label><caption><title>Key results.</title></caption><alternatives><graphic id="pcbi.1007023.t001g" xlink:href="pcbi.1007023.t001"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Key results presented in this paper.</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e005"><alternatives><graphic id="pcbi.1007023.e005g" xlink:href="pcbi.1007023.e005"/><mml:math id="M5"><mml:mi mathvariant="double-struck">I</mml:mi></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">If only one mtDNA species is controlled the variance of the controlled species reaches a constant value. When both species are controlled with equal strength their variances increase at identical rates, and, in general, the more tightly controlled species has a more slowly increasing variance (<xref ref-type="fig" rid="pcbi.1007023.g001">Fig 1</xref>). [D]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e006"><alternatives><graphic id="pcbi.1007023.e006g" xlink:href="pcbi.1007023.e006"/><mml:math id="M6"><mml:mtext mathvariant="double-struck">II</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">The mean energetic cost of maintaining a tissue can increase over time due to the nonlinear influence of mtDNA variance, even if the energetic demand on the tissue stays the same and mean levels of mtDNA are constant (<xref ref-type="disp-formula" rid="pcbi.1007023.e033">Eq 6</xref>). [D]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e007"><alternatives><graphic id="pcbi.1007023.e007g" xlink:href="pcbi.1007023.e007"/><mml:math id="M7"><mml:mtext mathvariant="double-struck">III</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">Intermediate heteroplasmy states can be more expensive than states homoplasmic in either mutant or wildtype. [C]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e008"><alternatives><graphic id="pcbi.1007023.e008g" xlink:href="pcbi.1007023.e008"/><mml:math id="M8"><mml:mtext mathvariant="double-struck">IV</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">A control lacking any mutant contribution can show an exponentially increasing cost, and the effects of particular cellular control strategies are more pronounced in low copy number cells (<xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3A and 3B</xref>). [D, C]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e009"><alternatives><graphic id="pcbi.1007023.e009g" xlink:href="pcbi.1007023.e009"/><mml:math id="M9"><mml:mtext mathvariant="double-struck">V</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">Control strategies based on the energy status of the cell can often outperform control based on mtDNA copy number or sensing mtDNA mass (which would work well for deficient deletion mutants, but would be suboptimal for deficient point mutations) (<xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3C</xref>). [D,C]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e010"><alternatives><graphic id="pcbi.1007023.e010g" xlink:href="pcbi.1007023.e010"/><mml:math id="M10"><mml:mtext mathvariant="double-struck">VI</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">Even for pathological mutants, reduction of mutant mtDNA alone is not always the optimal control strategy for a cell to adopt (<xref ref-type="fig" rid="pcbi.1007023.g004">Fig 4</xref>). [C]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e011"><alternatives><graphic id="pcbi.1007023.e011g" xlink:href="pcbi.1007023.e011"/><mml:math id="M11"><mml:mtext mathvariant="double-struck">VII</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">Tissues with high mean heteroplasmy levels will generally be harder to treat with mitochondrially targeted endonucleases if the heteroplasmy variance is high, especially if this high mean level is caused by a small percentage of cells (<xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6A and 6B</xref>). [D,T]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pcbi.1007023.e012"><alternatives><graphic id="pcbi.1007023.e012g" xlink:href="pcbi.1007023.e012"/><mml:math id="M12"><mml:mtext mathvariant="double-struck">VIII</mml:mtext></mml:math></alternatives></inline-formula>
</td><td align="left" rowspan="1" colspan="1">Weak long-term rather than short intense endonuclease treatments are more likely to beneficially impact mtDNA populations (<xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6D and 6E</xref>). [D,T]</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Here we present key results of this paper, which hold under the assumptions used in our models (see text and <xref ref-type="sec" rid="sec015">Discussion</xref>). We place in square brackets the models we invoke for each part: D&#x02014;our model for mitochondrial dynamics; C&#x02014;a particular illustrative family of cost functions; T&#x02014;a model for gene therapy.</p></fn></table-wrap-foot></table-wrap><p>What are the biological implications of these findings? A given mtDNA state (<italic>w</italic>, <italic>m</italic>) will accrue a cost to the cell, denoted by <italic>C</italic>(<italic>w</italic>, <italic>m</italic>), which can e.g. be an energetic cost or some other metric of tissue burden. If this cost function is nonlinear, increasing variances in <italic>w</italic> and <italic>m</italic> can lead to changes in mean cost &#x02329;<italic>C</italic>(<italic>w</italic>, <italic>m</italic>)&#x0232a; even when mean cellular copy numbers &#x02329;<italic>w</italic>&#x0232a;, &#x02329;<italic>m</italic>&#x0232a; remain constant (<xref ref-type="sec" rid="sec016">Methods</xref>) because the mean of a nonlinear function of random variables is not generally equal to the function of the mean of those variables (as seen above with cellular vs homogenate heteroplasmy). Therefore, the mean cost of maintaining a tissue may increase over time, even if tissue demands and mean mtDNA levels stay constant (<xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e013"><alternatives><graphic xlink:href="pcbi.1007023.e013.jpg" id="pcbi.1007023.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:mtext mathvariant="double-struck">II</mml:mtext></mml:math></alternatives></inline-formula>)). However, these increases may be small and their significance depends on the details of the cost function: hence the need to consider explicit forms, as we do in the next section.</p></sec></sec><sec id="sec006"><title>Cost: An effective mitochondrial energy-based cost function</title><p>Next, to find general quantitative principles underlying mitochondrial energy budgets, we build a cost function that assigns a cost to any given mtDNA state (<italic>w</italic>, <italic>m</italic>) and allows a general quantitative investigation of the tradeoffs in maintaining cellular mtDNA populations. The &#x02018;true&#x02019; energy budget of a cell with a given mitochondrial population is highly complex, involving many different metabolic processes in which mitochondria are involved [<xref rid="pcbi.1007023.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pcbi.1007023.ref046" ref-type="bibr">46</xref>]. We provide a simpler description, focussing on ATP production as a central mitochondrial function, and removing kinetic details in favour of a coarse-grained representation, to provide qualitative rather than quantitative results.</p><sec id="sec007"><title>General cost function structure</title><p>Three important terms involved in the energy status of a cell are: i) the energy demand <italic>D</italic>, ii) the net energy supply <italic>S</italic>, and iii) the efficiency of energy supply. Here we define efficiency as the amount of energy produced per unit of resource consumed. We included intuitive and general terms in our energy-based cost function, such as replication, degradation and maintenance costs, supply and demand, and resource availability. We seek a cost function that captures the idea that there might be an optimal number of mitochondria: not so few that each mitochondrion is inefficiently overworked and not so many that the burden of the mitochondrial population is itself large.</p><p>We express our effective cost function as:
<disp-formula id="pcbi.1007023.e014"><alternatives><graphic xlink:href="pcbi.1007023.e014.jpg" id="pcbi.1007023.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>C</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>|</mml:mo><mml:mi>D</mml:mi><mml:mo>-</mml:mo><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>|</mml:mo><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(2)</label></disp-formula>
where <italic>&#x003b1;</italic> is a scaling constant, and <italic>r</italic><sub><italic>i</italic></sub> gives the rate of resource consumption of a mitochondrion of type <italic>i</italic> (<italic>w</italic> or <italic>m</italic>). The second term assigns a cost to the use of resource. The terms in this cost function are expressed as rates: <italic>S</italic> and <italic>D</italic> correspond to net energy production (supply) and demand per unit time. Supply and demand terms are left deliberately generalisable to encompass the differences in metabolic poise between cell types. The demand can be considered to represent energy requirements of all cellular processes besides mitochondria (whose maintenance costs are incorporated in their net supply <italic>S</italic>(<italic>w</italic>, <italic>m</italic>)), which we assume to be constant. We are therefore modelling post-mitotic cells in stable environments, as demands are expected to change throughout the cell cycle. This cost function can be evaluated for any state (<italic>w</italic>, <italic>m</italic>) and assigns the lowest cost to a state that satisfies demand in the most efficient way.</p><p>The net energy production of a state (<italic>w</italic>, <italic>m</italic>), <italic>S</italic>(<italic>w</italic>, <italic>m</italic>), is modelled as
<disp-formula id="pcbi.1007023.e015"><alternatives><graphic xlink:href="pcbi.1007023.e015.jpg" id="pcbi.1007023.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>S</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>w</mml:mi><mml:mo>(</mml:mo><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003c1;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003c1;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>&#x003c1;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003c1;</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(3)</label></disp-formula>
where <italic>&#x003c1;</italic><sub>1,2,3</sub> are mitochondrial maintenance, building, and degradation costs, <italic>s</italic>(<italic>r</italic><sub><italic>w</italic></sub>) denotes the power production (in ATP/s) of a single wildtype mitochondrion given a resource consumption rate <italic>r</italic><sub><italic>w</italic></sub> (<xref ref-type="sec" rid="sec016">Methods</xref>, section 4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>), and &#x003bb; and <italic>&#x003bc;</italic> (which can be functions of <italic>w</italic> and <italic>m</italic>) denote the birth and death rates in units per second. Mutant mtDNA molecules are distinguished by the parameters <italic>&#x003f5;</italic><sub>1</sub>, <italic>&#x003f5;</italic><sub>2</sub> &#x02208; [0, 1] describing the mutant resource uptake rate (<italic>&#x003f5;</italic><sub>1</sub>) and efficiency (<italic>&#x003f5;</italic><sub>2</sub>) relative to that of the wildtypes (<italic>r</italic><sub><italic>m</italic></sub> = <italic>&#x003f5;</italic><sub>1</sub><italic>r</italic><sub><italic>w</italic></sub>). A low <italic>&#x003f5;</italic><sub>1</sub> could represent reduced flow through the electron transport chain due to e.g. damaged respiratory complexes, whereas a low <italic>&#x003f5;</italic><sub>2</sub> could denote increased proton leakage. Many mutants are known to have dysfunctional respiratory chain complexes [<xref rid="pcbi.1007023.ref047" ref-type="bibr">47</xref>], likely causing reduced electron flow through the respiratory chain and therefore reduced consumption rates of respiratory substrates such as NADH and oxygen. We therefore use <italic>&#x003f5;</italic><sub>1</sub> &#x0003c; 1 and <italic>&#x003f5;</italic><sub>2</sub> = 1 as our default choice (further described in section 4.7 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>), though settings with <italic>&#x003f5;</italic><sub>2</sub> &#x0003c; 1 are also investigated (section 5 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>).</p><p>The more detailed structure of our cost function, which has been relatively general so far, comes from specifying the relation <italic>s</italic>(<italic>r</italic><sub><italic>w</italic></sub>). In other words, how does the energy output of a mitochondrion depend on its resource (e.g. oxygen) consumption rate? We consider two possible forms for this function (section 3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>): a linear output relationship, suggested by some literature [<xref rid="pcbi.1007023.ref048" ref-type="bibr">48</xref>&#x02013;<xref rid="pcbi.1007023.ref050" ref-type="bibr">50</xref>], and a saturating relationship, which accounts for finite resource consumption and spare mitochondrial capacity [<xref rid="pcbi.1007023.ref051" ref-type="bibr">51</xref>, <xref rid="pcbi.1007023.ref052" ref-type="bibr">52</xref>] (section 5 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). We refer to these alternatives as the &#x02018;linear output model&#x02019; and the &#x02018;saturating output model&#x02019;. Both models are described in more detail in our Methods section (<xref ref-type="disp-formula" rid="pcbi.1007023.e034">Eq 7</xref>).</p><p>A trade-off between yield (efficiency) and rate of ATP production is present in yeast [<xref rid="pcbi.1007023.ref053" ref-type="bibr">53</xref>&#x02013;<xref rid="pcbi.1007023.ref055" ref-type="bibr">55</xref>] whose rate of ATP production due to respiration can become saturated at high resource levels or limited oxygen supply [<xref rid="pcbi.1007023.ref053" ref-type="bibr">53</xref>, <xref rid="pcbi.1007023.ref056" ref-type="bibr">56</xref>]. Higher energy production rates can then still be obtained by using fermentation at the expense of a lower yield [<xref rid="pcbi.1007023.ref053" ref-type="bibr">53</xref>]. A similar trade-off may exist in mitochondria, whose power production efficiency is higher when oxidizing NADH compared to oxidizing succinate [<xref rid="pcbi.1007023.ref050" ref-type="bibr">50</xref>]. The former may be the preferable substrate due to its higher yield, but if its levels become limiting an increase in the relative use of succinate would lower overall efficiency. When oxygen is limiting, increased glycolysis in an attempt to increase ATP production also leads to lower overall efficiency. These mechanisms could be the cause of a reduced power production efficiency at high energy demand, as proposed in our saturating output model. We will contrast our findings of the saturating output model with those generated by the linear output model.</p><p>We fitted the parameters of the linear output model using data provided in Ref. [<xref rid="pcbi.1007023.ref048" ref-type="bibr">48</xref>] (section 3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>), and set the parameters of the saturating model such that the two models behave similarly at low <italic>r</italic><sub><italic>i</italic></sub>. Further details on the choice of parameter values, and their biochemical interpretations, are given in section 4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>; default values are provided in <xref ref-type="supplementary-material" rid="pcbi.1007023.s013">S2 Table</xref>. For a given demand <italic>D</italic> we find the <italic>r</italic><sub><italic>w</italic></sub> which gives a demand-matching supply (details of the scenarios when supply cannot meet demand are given in section <xref ref-type="sec" rid="sec016">Methods</xref>). Given <italic>r</italic><sub><italic>w</italic></sub> we calculate <italic>r</italic><sub><italic>m</italic></sub> (using <italic>r</italic><sub><italic>m</italic></sub> = <italic>&#x003f5;</italic><sub>1</sub><italic>r</italic><sub><italic>w</italic></sub>) and so calculate the cost <italic>C</italic>(<italic>w</italic>, <italic>m</italic>).</p><p>In taking both the linear and saturating output models into consideration we have endeavoured to build the most general picture of a mitochondrial cost function that retains bottom-up interpretability. Where possible, we estimate associated parameter values based on experimental data. However, other cost function choices are certainly possible and can be analysed using the platform we present below: our objective here is to complement the generic result regarding cost functions in paragraph &#x0201c;Nonlinear cost functions predict changes in tissue maintenance.&#x0201d; with a specific reasonable choice of cost.</p></sec><sec id="sec008"><title>Intermediate heteroplasmies may be inefficient and resource availability can dictate the cost of mtDNA states</title><p><xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2</xref> shows heatmaps of the cost function in (<italic>w</italic>, <italic>m</italic>)-space for different mutant pathologies (modelled as different values of <italic>&#x003f5;</italic><sub>1</sub>). Our cost function generates a heteroplasmy threshold, its value depending on both <italic>w</italic><sub><italic>opt</italic></sub> and <italic>&#x003b4;</italic>, above which demand cannot be satisfied using oxidative phosphorylation (<xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2</xref>), though increased glycolysis may still maintain cell viability. The threshold effect is an established phenomenon in mitochondrial physiology [<xref rid="pcbi.1007023.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pcbi.1007023.ref014" ref-type="bibr">14</xref>].</p><fig id="pcbi.1007023.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.g002</object-id><label>Fig 2</label><caption><title>Intermediate heteroplasmies can be less efficient than either wildtype or mutant homoplasmy.</title><p>A visualization of the cost function in (<italic>w</italic>, <italic>m</italic>) space is shown for both saturating and linear output models, for various mutant pathologies (described by <italic>&#x003f5;</italic><sub>1</sub>). For visualization purposes, states in which cellular demand cannot be satisified are shown in white. Cells in these states may still survive by e.g. increasing glycolysis (effectively reducing mitochondrial demand). This figure assumes high copy numbers, results are qualitatively similar for low copy numbers. The actual cost values (given by the colour map) are of lesser importance for our findings, we rather focus on the qualitative shape of the cost function. <bold>A</bold>: The magenta (solid) and black (dashed) lines show the contour of the demand-satisfying region when demand is increased by 10%, or demand is increased by 50% and cellular resource availability is increased by 35%, respectively. <bold>B</bold>: The orange line corresponds to constant total copy number; moving up along this line increases heteroplasmy. Cells in region 1 or region 3 are more efficient, and show a lower cost, than cells in region 2. <bold>C</bold>: The linear mitochondrial output model does not show a decreased efficiency at intermediate heteroplasmy values.</p></caption><graphic xlink:href="pcbi.1007023.g002"/></fig><p>The state with lowest cost according to the linear output model is one with a minimum number of mitochondria required to satisfy demand (<xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2C</xref>), where these mitochondria respire as fast as possible. This would mean that this state of lowest cost has no spare capacity. Assuming a cell controls its mitochondrial population towards the state with lowest cost, the linear model predicts cells to lack spare capacity, contradicting experimental observations [<xref rid="pcbi.1007023.ref051" ref-type="bibr">51</xref>, <xref rid="pcbi.1007023.ref057" ref-type="bibr">57</xref>, <xref rid="pcbi.1007023.ref058" ref-type="bibr">58</xref>]. A saturating output model solves this problem (<xref ref-type="supplementary-material" rid="pcbi.1007023.s002">S2E Fig</xref> and <xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2A and 2B</xref>) and generates a trade-off between using each mitochondrion efficiently (minimising its resource consumption by increasing population) and minimising the cost of maintaining the total number of mitochondria (achieved by reducing the population). At low resource consumption, representing the linear regime of the saturating output model, the two models are similar.</p><p>We observe other qualitative differences in cost function structure between the saturating and linear output models. In the former, it is possible for intermediate heteroplasmy states to be more expensive than states homoplasmic for either species (<xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2A and 2B</xref>). Hence, in the saturating output model, it is possible for intermediate heteroplasmies to be the least efficient and the most expensive (<xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1007023.s004">S4 Fig</xref>, <xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e016"><alternatives><graphic xlink:href="pcbi.1007023.e016.jpg" id="pcbi.1007023.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:mtext mathvariant="double-struck">III</mml:mtext></mml:math></alternatives></inline-formula>)). This result arises from a tradeoff, when mutant load is increased, between a decrease in global efficiency and a reduction in resource consumption by the new mutants (section 5 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). The linear output model, on the other hand, always shows higher costs at higher heteroplasmy (for fixed total copy number) (<xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2C</xref>).</p><p>For our cost function, the existence of a high-cost intermediate heteroplasmy value is a relatively general feature of the saturating output model. We calculated the value of heteroplasmy with maximum cost (at constant total copy number), denoted by <italic>h</italic><sub><italic>max</italic></sub>, as a function of several model parameters. <italic>h</italic><sub><italic>max</italic></sub> = 1 (the homoplasmic mutant state) at values <italic>&#x003f5;</italic><sub>1</sub> &#x02272; 0.3 due to very low mutant functionality. However, at higher values of <italic>&#x003f5;</italic><sub>1</sub> (0.5 &#x02272; <italic>&#x003f5;</italic><sub>1</sub> &#x0003c; 1) we find <italic>h</italic><sub><italic>max</italic></sub> &#x0223c; (0.5&#x02013;0.8) over a large range of several of our cost function parameters (section 5.2 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). Though the size of the effect may be small, its existence alone is an interesting feature of our saturating output model.</p><p>It was previously found that it is possible for two mtDNA variants in mice to function normally at homoplasmy, but show deficiencies in heteroplasmic states [<xref rid="pcbi.1007023.ref059" ref-type="bibr">59</xref>]. While we do not claim that our model is the reason behind these observations it does suggest that differing resource consumption rates associated with distinct mtDNA species may play an important role.</p></sec></sec><sec id="sec009"><title>Combining cost and control: Comparison and optimisation of both cellular control and treatment strategies</title><sec id="sec010"><title>Timescales and energy sensing in optimal control of mtDNA populations</title><p>Here we compare the mean cost over time for four plausible cellular control strategies. The first two consist of the linear feedback model &#x003bb;(<italic>w</italic>, <italic>m</italic>) = <italic>&#x003bc;</italic> + <italic>c</italic><sub>1</sub>(<italic>w</italic><sub><italic>opt</italic></sub> &#x02212; (<italic>w</italic> + <italic>&#x003b4;m</italic>)) with (I) <italic>&#x003b4;</italic> = 0 (only wildtypes are sensed) and (II) <italic>&#x003b4;</italic> = 1 (total mtDNA copy number is controlled). We further identify optimal parameterisations (i.e. ones that minimise steady-state cost) of two control strategies, namely (III) a linear feedback control and (IV) the &#x02018;relaxed replication model&#x02019; (<xref ref-type="disp-formula" rid="pcbi.1007023.e030">Eq (5)</xref>) [<xref rid="pcbi.1007023.ref040" ref-type="bibr">40</xref>, <xref rid="pcbi.1007023.ref041" ref-type="bibr">41</xref>].</p><p>First, we fix the parameter values that are not being optimised. Our goal is to compare the costs of the dynamics resulting from each of the four controls, in the presence of mutants. In other words, we want to investigate whether some of these controls are better at protecting the cell (in the sense of maintaining a low energy cost) against mutant loads than others. To make this comparison fair, we demand that all controls yield the same dynamics in the absence of mutants: we set the wildtype mean and variance in this case to be identical under all controls. The mean is chosen to be <italic>w</italic><sub><italic>opt</italic></sub> (assuming that, without mutants, each control steers the population of wildtypes to its optimal value) and the variance is set by fixing the parameter <italic>&#x003b1;</italic><sub><italic>R</italic></sub> in the relaxed replication model to <italic>&#x003b1;</italic><sub><italic>R</italic></sub> = 10 (<xref ref-type="disp-formula" rid="pcbi.1007023.e030">Eq (5)</xref>), as its value was originally estimated to lie in the range (5&#x02013;17) [<xref rid="pcbi.1007023.ref040" ref-type="bibr">40</xref>]. This fixes the value for <italic>c</italic><sub>1</sub> in models (I)-(III) (<xref ref-type="supplementary-material" rid="pcbi.1007023.s014">S3 Table</xref>).</p><p>We now wish to optimise the parameters <italic>&#x003b4;</italic> and <italic>&#x003b7;</italic> in models (III) and (IV). These parameters have direct impact on how mutants are sensed by the cell, and are important in determining how the dynamics change when mutant load increases. We thus want to investigate i) whether there exists an optimal amount of mutant sensing, and ii) how the cost of the dynamics resulting from these optimal parameters <italic>&#x003b4;</italic><sub><italic>opt</italic></sub> and <italic>&#x003b7;</italic><sub><italic>opt</italic></sub> compares to that of our other two control strategies with <italic>&#x003b4;</italic> fixed at either 0 or 1. To do this, we require both an optimization time-scale <italic>T</italic> and a set of initial conditions. We use <italic>T</italic> = &#x0221e;, corresponding to the steady state limit, and initial heteroplasmy values in the range <italic>h</italic><sub>0</sub> &#x02208; [0, 0.2]; we later consider finite values of <italic>T</italic>.</p><p>Through stochastic simulations, we find that i) a control lacking any mutant contribution shows an exponential increase in cost over time, and ii) effects of particular control strategies are more pronounced in low copy number cells (<xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e017"><alternatives><graphic xlink:href="pcbi.1007023.e017.jpg" id="pcbi.1007023.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:mtext mathvariant="double-struck">III</mml:mtext></mml:math></alternatives></inline-formula>)) (<xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3</xref>). The relaxed replication rate control and our linear feedback function behave very similarly when <italic>&#x003b4;</italic> and <italic>&#x003b7;</italic> take their optimal values. Cost variances, as well as mutant and wildtype dynamics, are shown in <xref ref-type="supplementary-material" rid="pcbi.1007023.s006">S6 Fig</xref>. Model II shows an increase in mean cost over time while mean mutant and wildtype copy numbers remain constant (<xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3</xref> and <xref ref-type="supplementary-material" rid="pcbi.1007023.s006">S6 Fig</xref>)&#x02014;this is due to increases in copy number variances as argued previously.</p><fig id="pcbi.1007023.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.g003</object-id><label>Fig 3</label><caption><title>A control that senses no mutations shows an exponentially increasing cost, which is most noticeable in low copy number cells.</title><p><bold>A + B</bold>: Here we show the mean cost (3 &#x000d7; 10<sup>4</sup> repeats) for the following four controls: linear feedback controls &#x003bb;(<italic>w</italic>, <italic>m</italic>) = <italic>&#x003bc;</italic> + <italic>c</italic><sub>1</sub>(<italic>w</italic><sub><italic>opt</italic></sub> &#x02212; (<italic>w</italic> + <italic>&#x003b4;m</italic>)) with I) <italic>&#x003b4;</italic> = 0, II) <italic>&#x003b4;</italic> = 1, and III) <italic>&#x003b4;</italic> = <italic>&#x003b4;</italic><sub><italic>opt</italic></sub>, and IV) the optimised &#x02018;relaxed replication control&#x02019; [<xref rid="pcbi.1007023.ref040" ref-type="bibr">40</xref>, <xref rid="pcbi.1007023.ref041" ref-type="bibr">41</xref>] (<xref ref-type="disp-formula" rid="pcbi.1007023.e030">Eq (5)</xref>). Controls were initialised in steady state at <italic>h</italic><sub>0</sub> = 0.15. Both figures used the saturating output model; figures (A) and (B) correspond to low and high copy number cells, respectively. We used <italic>&#x003f5;</italic><sub>1</sub> = 0.3; other control parameters used are specified in section 5.3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. <bold>C: A control based on sensing mitochondrial energy output is generally a good strategy</bold>. This plot shows the optimal value of <italic>&#x003b4;</italic> in our linear control as a function of <italic>&#x003f5;</italic><sub>1</sub>, for the linear and saturating model and for both low (<italic>h</italic><sub>0</sub> = 0.1, solid line) and high (<italic>h</italic><sub>0</sub> = 0.8, dashed line) initial heteroplasmies. Here we used <italic>T</italic> = 100 and high copy number values for both models. Similar plots for <italic>T</italic> = 10<sup>4</sup> are shown in <xref ref-type="supplementary-material" rid="pcbi.1007023.s007">S7 Fig</xref>, section 5.3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. In the linear model <italic>&#x003b4;</italic><sub><italic>opt</italic></sub> becomes negative for low <italic>&#x003f5;</italic><sub>1</sub> values; as mutant copy number increases, a negative <italic>&#x003b4;</italic> leads to an increase in wildtype to compensate for the deficient mutants.</p></caption><graphic xlink:href="pcbi.1007023.g003"/></fig><p>We now investigate how the optimal value of mutant sensing for the linear control (<italic>&#x003b4;</italic><sub><italic>opt</italic></sub>) depends on timescale <italic>T</italic>, initial heteroplasmy <italic>h</italic><sub>0</sub> and the &#x02018;mutant pathology level&#x02019; described by <italic>&#x003f5;</italic><sub>1</sub>. Here, we use the term &#x02018;mutation pathology level&#x02019; to refer to a lower energy production rate of mutants due to a lower resource consumption rate, while &#x02018;mutant sensing&#x02018;, as explained earlier, is used as a more general term. Intuitively, values of <italic>&#x003f5;</italic><sub>1</sub> &#x02243; 1 have <italic>&#x003b4;</italic><sub><italic>opt</italic></sub> &#x02248; 1: when wildtypes and mutants are equivalent, having a steady state with <italic>w</italic> + <italic>m</italic> = <italic>w</italic><sub><italic>opt</italic></sub> is desirable.</p><p>Values for <italic>&#x003b4;</italic><sub><italic>opt</italic></sub> were found for the linear and saturating models, with low and high initial heteroplasmy values, for <italic>T</italic> = 100 days (<xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3C</xref>). Having <italic>&#x003b4;</italic> &#x02248; 1 means wildtypes and mutants are fed back similarly, whereas when <italic>&#x003b4;</italic> &#x0226a; 1 mutants are fed back less. For very deficient mutants (low <italic>&#x003f5;</italic><sub>1</sub>), a low <italic>&#x003b4;</italic><sub><italic>opt</italic></sub> ensures that wildtype copy number remains close to its optimal value to compensate for the mutants. Generally, as <italic>&#x003f5;</italic><sub>1</sub> decreases, <italic>&#x003b4;</italic><sub><italic>opt</italic></sub> decreases (<xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3C</xref>). Similar results are found for longer timescales <italic>T</italic> (section 5.3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>).</p><p>If mitochondrial energy outputs are sensed, the quantity &#x02018;<italic>w</italic> + <italic>&#x003b4;m</italic>&#x02019; represents the mitochondrial energy production rate (power production). In this case, a mutant with low <italic>&#x003f5;</italic><sub>1</sub> produces less energy and is thus sensed less (low <italic>&#x003b4;</italic>). The relation between <italic>&#x003f5;</italic><sub>1</sub> and <italic>&#x003b4;</italic> now obeys the optimal trend shown in <xref ref-type="fig" rid="pcbi.1007023.g003">Fig 3C</xref>. Therefore, control strategies based on the energy status of the cell can often outperform controls based on mtDNA copy number (which always have <italic>&#x003b4;</italic> = 1) or sensing mtDNA mass (which would work well for deficient deletion mutants, but would be suboptimal for deficient point mutations) (<xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e018"><alternatives><graphic xlink:href="pcbi.1007023.e018.jpg" id="pcbi.1007023.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:mtext mathvariant="double-struck">IV</mml:mtext></mml:math></alternatives></inline-formula>)). Control based on copy number is preferred when a mutant is nearly as functional as a wildtype, in which case energy output and copy number are very much related. We have not used the expression for energy output in our cost function as a control strategy itself because claims based on the linear function <italic>w</italic> + <italic>&#x003b4;m</italic> are more general than one based on the details of our cost function.</p></sec><sec id="sec011"><title>Locally optimal control strategies map the control space of mtDNA populations</title><p>Our cost function allows us to identify locally optimal controls: controls that, for each state (<italic>w</italic>, <italic>m</italic>), move the system in the direction of the largest decrease in cost. The resulting dynamics are shown in <xref ref-type="fig" rid="pcbi.1007023.g004">Fig 4</xref>. When heteroplasmy is high, the main priority is not always to decrease mutant copy number, but to increase wildtype copy number even if this means an increase in mutant load (region 2 in <xref ref-type="fig" rid="pcbi.1007023.g004">Fig 4A</xref>). Only after wildtype copy number has sufficiently increased should the focus be on decreasing <italic>m</italic>. At high copy numbers, the optimal dynamics are to decrease all mtDNA in an evenhanded manner (region 1) rather than decreasing <italic>m</italic> at a faster rate than <italic>w</italic>. For the saturating model, there is a divergence point in the space of local optimal strategies, reflecting the two local cost minima (high wildtype and high mutant) observed earlier (<xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2</xref>). Hence, there are several regions of state space where even for pathological mutants, reduction of mutant mtDNA alone is not always the optimal control strategy (<xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e019"><alternatives><graphic xlink:href="pcbi.1007023.e019.jpg" id="pcbi.1007023.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:mtext mathvariant="double-struck">V</mml:mtext></mml:math></alternatives></inline-formula>)). Finally, the less pathological the mutants become (e.g. <xref ref-type="fig" rid="pcbi.1007023.g004">Fig 4B</xref>), the more the locally optimal control starts to resemble a linear control. In the linear output model, the optimal control always shows linear behaviour (<xref ref-type="fig" rid="pcbi.1007023.g004">Fig 4C</xref>).</p><fig id="pcbi.1007023.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.g004</object-id><label>Fig 4</label><caption><title>Locally optimal controls show nonlinear behaviours close to demand-satisfying regions, but linear optimal dynamics far away from these regions.</title><p>Streamplots in (<italic>w</italic>, <italic>m</italic>)-space show the dynamics resulting from a locally optimal control, for various parameters of <italic>&#x003f5;</italic><sub>1</sub>. At each point, arrows show the direction corresponding to the largest decrease in cost. Regions are coloured according to the magnitude of the decrease in cost when moving in the optimal direction. Black arrows illustrate general trends in these regions. <bold>A</bold>: Region (1) shows that at high copy numbers, both mutant and wildtype mtDNAs should be decreased in an evenhanded manner; region (2) shows the possibility that the optimal control involves an increase in mutant copy number. <bold>B</bold>: A higher value for the parameter <italic>&#x003f5;</italic><sub>1</sub> is used, meaning mutants are less pathological. <bold>C</bold>: the locally optimal control for the linear output model more closely resembles a linear control. In both (A) and (B) we see a divergence point (red asterisk) illustrating the fact that both high mutant and high wildtype states constitute local attractors of low cost (as in <xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2</xref>).</p></caption><graphic xlink:href="pcbi.1007023.g004"/></fig></sec><sec id="sec012"><title>A parameterised model of artificial mtDNA control for disease treatment</title><p>In the previous section we identified locally optimal control strategies. Of course, these strategies may not be achievable by the cell (e.g. the cell may not be able to decouple biogenesis of wildtype and mutant mtDNA). However, such controls may still be possible through human intervention. This is why, in this section, we model recently developed genetic treatments to artificially control mtDNA populations. We then combine this treatment model with our linear feedback control &#x003bb;(<italic>w</italic>, <italic>m</italic>) and our cost function.</p><p>Mitochondrially targeted zinc finger nucleases (mtZFNs) [<xref rid="pcbi.1007023.ref035" ref-type="bibr">35</xref>, <xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>, <xref rid="pcbi.1007023.ref060" ref-type="bibr">60</xref>&#x02013;<xref rid="pcbi.1007023.ref062" ref-type="bibr">62</xref>] are able to produce shifts in heteroplasmy by specifically cutting mutant mtDNA. To develop quantitative theory to understand and tune the effects of these interventions, we model nuclease transfection as inducing selective increases in mtDNA degradation, on the background of the linear cellular feedback control introduced earlier. Our transfection model contains three parameters describing strength (<italic>I</italic><sub>0</sub>), duration (<italic>b</italic>), and selectivity (<italic>&#x003be;</italic>) of nuclease treatment (<xref ref-type="sec" rid="sec016">Methods</xref>). We assume that for every mutant that is cleaved by the endonucleases, <italic>&#x003be;</italic> wildtypes are cleaved [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. For example, when <italic>&#x003be;</italic> = 1 there is no distinction between mutants and wildtypes, and when <italic>&#x003be;</italic> = 0 there is no off-target cleavage.</p><p>We fit these treatment parameters, as well as our feedback control parameters <italic>c</italic><sub>1</sub> and <italic>&#x003b4;</italic>, to recently obtained experimental data [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. These data involve heteroplasmy and mtDNA copy number measurements during iterative treatments with mtZFNs of 80% heteroplasmic human osteosarcoma 143B cybrid cells. Four sequential cycles of transfection and recovery were performed, where each recovery period lasted 28 days [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. We use the data provided in Ref. [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>] as well as additional data from this reference which was not explicitly provided in the paper. For the current study, we have collected new data consisting of: i) measurements of total mtDNA copy number in pre-treatment cells (which are used as initial conditions in our inference model), and ii) measurements of mtZFN expression profiles (<xref ref-type="supplementary-material" rid="pcbi.1007023.s009">S9 Fig</xref>).</p></sec><sec id="sec013"><title>A Bayesian description of nuclease treatment</title><p>We use Metropolis sampling to obtain posterior distributions of the parameters <italic>I</italic><sub>0</sub>, <italic>b</italic>, <italic>&#x003be;</italic>, <italic>c</italic><sub>1</sub> and <italic>&#x003b4;</italic> (<xref ref-type="sec" rid="sec016">Methods</xref>). Bayesian credible intervals for heteroplasmy and total copy number values during four consecutive rounds of treatment are shown in <xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5A and 5B</xref>, illustrating the ability of this simple model to capture the dynamics resulting from nuclease activity. A periodicity of 28 days was imposed, representing the experimental protocol (<xref ref-type="sec" rid="sec016">Methods</xref>).</p><fig id="pcbi.1007023.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.g005</object-id><label>Fig 5</label><caption><title>Bayesian credible intervals show the ability of a simple nuclease treatment model to capture experimental observations.</title><p>We used Metropolis sampling to fit our model parameters to recently obtained experimental data [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. Solid black lines correspond to the maximum a posteriori (MAP) prediction and vertical dashed lines indicate transfection events (once every 28 days). <bold>A</bold>: Drawing from our posterior distributions (5 &#x000d7; 10<sup>4</sup> samples), we show the mean and 50% and 95% credible intervals of our heteroplasmy dynamics predictions during four rounds of treatment and recovery. Deterministic simulations were used. Crosses indicate data points from Ref. citeGammage16Near. <bold>B</bold>: Similar to figure (A), but showing relative total mtDNA copy numbers. <bold>C + D</bold>: Heteroplasmy and copy number dynamics were measured during a single round of treatment and recovery in a setting in which the mtZFN concentration was reduced by incorporating hammerhead ribozymes in the mtZFN backbone [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. The credible intervals shown were obtained by sampling from the posterior distributions of the parameters <italic>I</italic><sub>0</sub>, <italic>b</italic>, <italic>c</italic><sub>1</sub> and <italic>&#x003b4;</italic> obtained using the data in figures (A) and (B), and using <italic>&#x003be;</italic> &#x0223c; 0.15 which represents the maximum likelihood estimate of <italic>&#x003be;</italic> using this low mtZFN concentration data (<xref ref-type="sec" rid="sec016">Methods</xref>). Error bars in figure (D) show standard deviations of experimental measurements [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>].</p></caption><graphic xlink:href="pcbi.1007023.g005"/></fig><p>Our inference suggests the selectivity parameter <italic>&#x003be;</italic> to lie in the range 0.6&#x02013;0.8, indicating high levels of off-target cleavage (<xref ref-type="supplementary-material" rid="pcbi.1007023.s010">S10 Fig</xref>). This is not surprising given the large drop in total copy number (as low as &#x0223c;5% of initial values) combined with a modest shift in heteroplasmy (from 0.8 to &#x0223c; 0.6) upon the first treatment. Supporting the high off-target cleavage, mtZFNs not targeted to any mtDNA sequence reduced copy numbers to 25% of their original values [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>].</p><p>We now investigate whether our model can account for additional data (obtained in Ref. [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]) consisting of heteroplasmy and copy number measurements in a setting in which the concentration of mtZFNs is reduced by incorporating hammerhead ribozymes in the mtZFN backbone (for details, see Ref. [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]). A single round of treatment and recovery in this setting led to a large shift in heteroplasmy, from <italic>h</italic> &#x02248; 0.8 to <italic>h</italic> &#x02248; 0.2, and a drop in copy number similar to the previous setting in which mtZFN concentrations were higher (after 24 hours, mtDNA copy number dropped to &#x0223c;20% of its original value) [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>]. These observations indicate that lower mtZFN concentrations lead to the treatment being more selective and, surprisingly, of similar strength. Because the additional data involves a different experimental setup inducing a large increase in selectivity, we adjust the parameter <italic>&#x003be;</italic> to fit this additional data by finding its maximum likelihood estimate (<xref ref-type="sec" rid="sec016">Methods</xref>) but use posterior samples for all other parameters (obtained from inference based only on the data shown in <xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5A and 5B</xref>). We find, consonant with an improved selectivity of this modified protocol, that <italic>&#x003be;</italic> &#x02248; 0.15 in this low mtZFN concentration setting (<xref ref-type="sec" rid="sec016">Methods</xref>) and that our model can reproduce the heteroplasmy and copy number dynamics using our previously fitted parameters <italic>I</italic><sub>0</sub>, <italic>b</italic>, <italic>c</italic><sub>1</sub> and <italic>&#x003b4;</italic> (<xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5C and 5D</xref>).</p><p>Finally, we measured transient expression profiles of mtZFNs using the same transfection protocol as in Ref. [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>] (<xref ref-type="supplementary-material" rid="pcbi.1007023.s009">S9 Fig</xref>). Posterior samples of the parameters <italic>I</italic><sub>0</sub> and <italic>b</italic> predict that mtZFN levels have dropped to very low levels 5 days post-transfection in the setting without hammerhead ribozymes, consistent with our obtained experimental data (<xref ref-type="supplementary-material" rid="pcbi.1007023.s011">S11 Fig</xref>). We thus show that our model is capable of capturing the dynamics of several data sets. Our mtZFN treatment model predicts that total copy number reaches a minimum at around 3 days (<xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5B and 5D</xref>).</p></sec><sec id="sec014"><title>Knowledge of the heteroplasmy distribution of a tissue is important in determinining how effciently the tissue can be treated</title><p>To explore the effect of the heteroplasmy distribution on treatment efficacy, we consider three initial <italic>h</italic> distributions with different variances but identical homogenate means. We treat these populations multiple times using the parameter fits obtained in the previous section. The resulting shifts in heteroplasmy distribution, including mean and threshold-crossing probability, are shown in <xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6A and 6B</xref>. High heteroplasmy variances require many cells close to the two extremes <italic>h</italic> = 0 and <italic>h</italic> = 1, which are challenging to shift. A striking reduction in treatment efficacy is predicted as heteroplasmy variance increases while fixing its mean (<xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6A and 6B</xref>). Threshold crossing probability (for example, <italic>P</italic>(<italic>h</italic> &#x0003e; 0.6)) also becomes harder to shift at higher variance. We conclude that tissues with a high mean heteroplasmy level will generally be harder to treat if the heteroplasmy variance is high, especially if this high mean level is caused by a small percentage of cells.</p><fig id="pcbi.1007023.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1007023.g006</object-id><label>Fig 6</label><caption><title>Knowledge of the heteroplasmy distribution is important in predicting how efficiently a tissue can be treated.</title><p><bold>A + B</bold>: The effect of four simulated consecutive treatments on three different initial heteroplasmy distributions is shown; all initial distributions have identical means (&#x02329;<italic>h</italic>&#x0232a; = 0.8) but different variances (increasing from left to right). The higher the variance of the initial population, the harder to shift mean heteroplasmy values; mean values after each treatment as well as <italic>P</italic>(<italic>h</italic> &#x0003e; 0.6) are shown in figure (B). In these simulations we assumed that every cell gets transfected. <bold>Gentle but sustained treatments induce larger heteroplasmy shifts than hard and brief treatments. C</bold>: Both the linear and saturating model show a sharp drop in the optimal treatment strength <italic>I</italic><sub>0,<italic>opt</italic></sub> as the mutants become more functional (i.e. as <italic>&#x003f5;</italic><sub>1</sub> increases). <bold>D</bold>: Means and variances of mutant and wildtype copy numbers were simulated during a round of treatment and recovery, using: i) parameters fitted to the data shown in <xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5A and 5B</xref> (blue), ii) a longer treatment duration (smaller <italic>b</italic>, green) and iii) a higher selectivity (smaller <italic>&#x003be;</italic>, magenta). MtZFN levels first drop below 5% of their maximum values after &#x0223c;4.5 and &#x0223c;35 days for the short (blue, magenta) and long (green) treatments, respectively. The longer weaker treatment induces higher heteroplasmy shifts than the shorter stronger treatment. <italic>&#x003f5;</italic><sub>1</sub> = 0.2 was used, the corresponding cost heatmap is shown. Error bars show standard deviations (based on 10<sup>4</sup> stochastic simulations), further detailed are given in section 6.6 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. <bold>E</bold>: This figure also illustrates that gentle sustained treatments lead to larger heteroplasmy shifts. Examples of treatment trajectories are shown; after a single treatment, an initial heteroplasmy of 0.8 is mapped to 0.53 (short strong treatment) or 0.39 (long weak treatment). Parameters chosen in figures (A)&#x02013;(E) are based on the inference performed earlier, their exact values are provided in section 6.6 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>.</p></caption><graphic xlink:href="pcbi.1007023.g006"/></fig><p>We can use our parameterised theory to find optimal treatment strengths <italic>I</italic><sub>0,<italic>opt</italic></sub> for a given system. <xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6C</xref> shows <italic>I</italic><sub>0,<italic>opt</italic></sub> as a function of <italic>&#x003f5;</italic><sub>1</sub>. Intuitively, the strongest treatment should be given to the least functional mutants, and when mutants are almost as functional as wildtypes it is preferable not to treat at all. The optimal treatment strength drops rather sharply as <italic>&#x003f5;</italic><sub>1</sub> increases, and does so sooner for the saturating model. This last observation may be because at some point reducing heteroplasmy becomes more expensive as can be seen in <xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2B</xref>. Optimal treatment strengths for longer treatments (higher <italic>b</italic>) show similar qualitative behaviour.</p><p>
<xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6D</xref> shows trajectories in (<italic>w</italic>, <italic>m</italic>) space throughout a single treatment and recovery phase. The three trajectories shown correspond to: i) a short and strong treatment, ii) a long and weak treatment, and iii) a short but more selective treatment. The value for <italic>I</italic><sub>0</sub> was chosen such that, for the specific treatment duration <italic>b</italic> used and given a fixed total simulation time, the shift in heteroplasmy was largest. For the short treatment a relatively large proportion of time is spent fluctuating around steady state values (dynamics which do not change mean <italic>h</italic>) due to a relatively quick recovery, whereas for longer treatments more time is spent in the treatment phase itself (dynamics which lower mean <italic>h</italic>). We thus find that in a given time frame, treating longer but weaker results in a lower final heteroplasmy value than treating short and strong (<xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>(<inline-formula id="pcbi.1007023.e020"><alternatives><graphic xlink:href="pcbi.1007023.e020.jpg" id="pcbi.1007023.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mtext mathvariant="double-struck">VIII</mml:mtext></mml:math></alternatives></inline-formula>)). A weaker treatment also reduces the chance of a cell losing all its mtDNA molecules. Intuitively, a more selective treatment leads to larger heteroplasmy shifts.</p><p>Nuclease treatment and a subsequent recovery phase will have the net effect of mapping an initial heteroplasmy value <italic>h</italic><sub><italic>i</italic></sub> to a mean final heteroplasmy value, <italic>h</italic><sub><italic>f</italic></sub>. We simulated this mapping in the presence of cellular feedback control (<xref ref-type="fig" rid="pcbi.1007023.g006">Fig 6E</xref>), finding that heteroplasmy shifts are largest for intermediate heteroplasmies. The difference in treatment results for long compared to short treatments is also illustrated. Interestingly, for high <italic>h</italic> values, it is possible to end up with a <bold>higher</bold> heteroplasmy value after treatment, especially if <italic>&#x003be;</italic> &#x02243; 1 (<xref ref-type="supplementary-material" rid="pcbi.1007023.s008">S8 Fig</xref>).</p></sec></sec></sec><sec sec-type="conclusions" id="sec015"><title>Discussion</title><p>In this work, we have built a quantitative theory bridging stochastic optimal control, costs of mtDNA populations, and gene therapies. Our results contribute to a growing body of evidence [<xref rid="pcbi.1007023.ref063" ref-type="bibr">63</xref>&#x02013;<xref rid="pcbi.1007023.ref066" ref-type="bibr">66</xref>] that the variance of mtDNA populations has important physiological and therapeutic implications independently of mean heteroplasmy, and underline that stochastic theory is required to understand this biologically and medically important quantity.</p><p>Key findings of our model (<xref rid="pcbi.1007023.t001" ref-type="table">Table 1</xref>) include (<inline-formula id="pcbi.1007023.e021"><alternatives><graphic xlink:href="pcbi.1007023.e021.jpg" id="pcbi.1007023.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:mi mathvariant="double-struck">I</mml:mi></mml:math></alternatives></inline-formula>) the identification of tradeoffs in the control of one or the other mtDNA species; (<inline-formula id="pcbi.1007023.e022"><alternatives><graphic xlink:href="pcbi.1007023.e022.jpg" id="pcbi.1007023.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:mtext mathvariant="double-struck">II</mml:mtext></mml:math></alternatives></inline-formula>) the observation that increasing mtDNA variance can lead to increased energetic costs over time and ageing even when means and demands are preserved; (<inline-formula id="pcbi.1007023.e023"><alternatives><graphic xlink:href="pcbi.1007023.e023.jpg" id="pcbi.1007023.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:mtext mathvariant="double-struck">III</mml:mtext></mml:math></alternatives></inline-formula>) intermediate heteroplasmy states can be more expensive than states homoplasmic in either mutant or wildtype; (<inline-formula id="pcbi.1007023.e024"><alternatives><graphic xlink:href="pcbi.1007023.e024.jpg" id="pcbi.1007023.e024g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M24"><mml:mtext mathvariant="double-struck">IV</mml:mtext></mml:math></alternatives></inline-formula>) mutant sensing can be required to avoid an exponentially increasing cost; (<inline-formula id="pcbi.1007023.e025"><alternatives><graphic xlink:href="pcbi.1007023.e025.jpg" id="pcbi.1007023.e025g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M25"><mml:mtext mathvariant="double-struck">V</mml:mtext></mml:math></alternatives></inline-formula>) sensing of cellular energetic status can be more effective than other targets like mitochondrial mass; (<inline-formula id="pcbi.1007023.e026"><alternatives><graphic xlink:href="pcbi.1007023.e026.jpg" id="pcbi.1007023.e026g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M26"><mml:mtext mathvariant="double-struck">VI</mml:mtext></mml:math></alternatives></inline-formula>) reduction of mutant mtDNA alone is not always the optimal control strategy; (<inline-formula id="pcbi.1007023.e027"><alternatives><graphic xlink:href="pcbi.1007023.e027.jpg" id="pcbi.1007023.e027g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M27"><mml:mtext mathvariant="double-struck">VII</mml:mtext></mml:math></alternatives></inline-formula>) high heteroplasmy variance challenges gene therapy treatments; and (<inline-formula id="pcbi.1007023.e028"><alternatives><graphic xlink:href="pcbi.1007023.e028.jpg" id="pcbi.1007023.e028g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M28"><mml:mtext mathvariant="double-struck">VIII</mml:mtext></mml:math></alternatives></inline-formula>) weak, long gene therapy trajectories are more effective than short, intense ones.</p><p>Our findings hold qualitatively under the range of conditions we discuss above. The aim of our manuscript is not to make detailed quantitative predictions and conclusions based on complex models, nor do we intend to imply that our models are the only possible models one could construct. Rather, we aim to provide general biologically plausible models to gain qualitative insights and to comment on large-scale behaviours. To this end, our cost function, used to illustrate some of our results, is phenomenological and contains several parameters. Most of these are biologically interpretable, meaning their values can be obtained or estimated from the literature. The main elements in our cost function are quite general: terms involving supply, demand, and resource.</p><p>To test the qualitative shape of our cost function, one could sort cells based on mitochondrial copy number and heteroplasmy to obtain samples at different points in (<italic>w</italic>, <italic>m</italic>) space. Measurements of e.g. cell proliferation, ROS or apoptosis rates allow for the evaluation of an effective cost at each of these points. By measuring the relative consumption rates of NADH and succinate, as well as the amount of ATP produced per glucose consumed, in identical cells exposed to different energy demands, the saturating output model may be probed.</p><p>If the parameter <italic>&#x003b4;</italic> is low, i.e. mutants are sensed less, mutant copy numbers at high heteroplasmies will be higher than wildtype copy numbers at low heteroplasmies. Experimentally, it has been observed that heteroplasmic cells can have total mtDNA copy number values that are 5-17-fold higher compared to cells homoplasmic in wildtype [<xref rid="pcbi.1007023.ref067" ref-type="bibr">67</xref>&#x02013;<xref rid="pcbi.1007023.ref070" ref-type="bibr">70</xref>]. The cell has somehow allowed these mutants to expand, which may mean that they are less tightly controlled; controls based on total energy output or mtDNA mass (which can result in <italic>&#x003b4;</italic> &#x0003c; 1) may lead to such behaviours. A control on mtDNA mass could explain why deletion mutants are often seen to expand [<xref rid="pcbi.1007023.ref071" ref-type="bibr">71</xref>, <xref rid="pcbi.1007023.ref072" ref-type="bibr">72</xref>] and would also predict normal copy number levels in cells harbouring mtDNA point mutations. Recently, it was found that samples with mtDNA indels had very high mtDNA copy number levels, but single nucleotide variants did not [<xref rid="pcbi.1007023.ref073" ref-type="bibr">73</xref>].</p><p>We showed that heteroplasmy distributions in cell populations can provide important information about the possibility of successfully treating these cells with endonucleases. A tissue may be harder to treat if its high mean heteroplasmy level is caused by a small percentage of dysfunctional cells. Experimental values of mean homogenate heteroplasmy in heart tissue of patients with the 3243A&#x0003e;G mutation are roughly around 0.8 (though ranges can be large [<xref rid="pcbi.1007023.ref074" ref-type="bibr">74</xref>&#x02013;<xref rid="pcbi.1007023.ref077" ref-type="bibr">77</xref>]) and muscle tissue often shows mosaic structures, with deficient patches of cells adjacent to healthy cells. These examples show that it may be that, at least in some cases, high mean levels are indeed caused by a relatively low percentage of cells, meaning that there are still challenges ahead for efficiently treating these tissues.</p><p>One of the features of our cost function is that resource limitations play an important role in shaping the cost landscape. There are indications that cellular levels of NAD (a coenzyme involved in oxidative phosphorylation) are limiting, and that a sufficient supply of NAD to mitochondria becomes critical [<xref rid="pcbi.1007023.ref078" ref-type="bibr">78</xref>&#x02013;<xref rid="pcbi.1007023.ref081" ref-type="bibr">81</xref>]. An increase of intracellular NAD can lead to an increase in oxygen consumption and ATP production [<xref rid="pcbi.1007023.ref081" ref-type="bibr">81</xref>] indicating that resource limitation may, at least in some cases, be a genuine constraint. Adding various kinds of resources can significantly change mitochondrial basal respiration rate [<xref rid="pcbi.1007023.ref082" ref-type="bibr">82</xref>&#x02013;<xref rid="pcbi.1007023.ref084" ref-type="bibr">84</xref>].</p><p>Like any other model, our models have a defined range of applicability. A key baseline assumption was using identical replication and degradation rates for mutants and wildtypes. Various possibilities of distinct rates have been offered in the literature, including faster mutant replication rates [<xref rid="pcbi.1007023.ref022" ref-type="bibr">22</xref>, <xref rid="pcbi.1007023.ref068" ref-type="bibr">68</xref>, <xref rid="pcbi.1007023.ref085" ref-type="bibr">85</xref>&#x02013;<xref rid="pcbi.1007023.ref088" ref-type="bibr">88</xref>], lower mutant degradation rates [<xref rid="pcbi.1007023.ref089" ref-type="bibr">89</xref>], and higher mutant degradation rates [<xref rid="pcbi.1007023.ref090" ref-type="bibr">90</xref>, <xref rid="pcbi.1007023.ref091" ref-type="bibr">91</xref>]. Including such differences, and other features such as <italic>de novo</italic> mutations, degradation control, and cell divisions [<xref rid="pcbi.1007023.ref038" ref-type="bibr">38</xref>, <xref rid="pcbi.1007023.ref064" ref-type="bibr">64</xref>, <xref rid="pcbi.1007023.ref092" ref-type="bibr">92</xref>, <xref rid="pcbi.1007023.ref093" ref-type="bibr">93</xref>], constitute natural extensions to our theory.</p></sec><sec sec-type="materials|methods" id="sec016"><title>Methods</title><sec id="sec017"><title>Wildtype and mutant mtDNA evolution equations</title><p>Wildtype and mutant mtDNA copy numbers are considered to have birth rate &#x003bb;(<italic>w</italic>, <italic>m</italic>) = <italic>&#x003bc;</italic> + <italic>c</italic><sub>1</sub>(<italic>w</italic><sub><italic>opt</italic></sub> &#x02212; (<italic>w</italic> + <italic>&#x003b4;m</italic>)) and death rate <italic>&#x003bc;</italic>, leading to the following evolution equations:
<disp-formula id="pcbi.1007023.e029"><alternatives><graphic xlink:href="pcbi.1007023.e029.jpg" id="pcbi.1007023.e029g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M29"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mrow><mml:mo>=</mml:mo><mml:mi>w</mml:mi><mml:mo>(</mml:mo><mml:mo>&#x003bb;</mml:mo><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mrow><mml:mo>=</mml:mo><mml:mi>m</mml:mi><mml:mo>(</mml:mo><mml:mo>&#x003bb;</mml:mo><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(4)</label></disp-formula></p><p>The corresponding stochastic system, required to e.g. describe fixation, does not have an explicit solution due to nonlinearities. The deterministic steady state solution of <xref ref-type="disp-formula" rid="pcbi.1007023.e029">Eq (4)</xref> is given by (<italic>w</italic><sub><italic>ss</italic></sub> + <italic>&#x003b4;m</italic><sub><italic>ss</italic></sub>) = <italic>w</italic><sub><italic>opt</italic></sub> and represents a straight line in (<italic>w</italic>, <italic>m</italic>)-space (<xref ref-type="supplementary-material" rid="pcbi.1007023.s001">S1A Fig</xref>), whose slope depends on the value of <italic>&#x003b4;</italic>. Stochastic dynamics will fluctuate around the steady state line, causing heteroplasmy to change over time until fixation of either species occurs. This means that, over long times, a cell will reach either <italic>h</italic> = 0 or <italic>h</italic> = 1 (in the absence of mutations). When mutations do occur, a cell will always reach a state with <italic>h</italic> = 1 (though many different mutant species may be present).</p></sec><sec id="sec018"><title>Relaxed replication model</title><p>The relaxed replication model assumes a constant death rate <italic>&#x003bc;</italic> and a birth rate of the form
<disp-formula id="pcbi.1007023.e030"><alternatives><graphic xlink:href="pcbi.1007023.e030.jpg" id="pcbi.1007023.e030g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M30"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mo>&#x003bb;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b7;</mml:mi><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo><mml:mo>+</mml:mo><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b7;</mml:mi><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(5)</label></disp-formula>
with <italic>&#x003b1;</italic><sub><italic>R</italic></sub> &#x0003e; 1 and <italic>&#x003b7;</italic> constants [<xref rid="pcbi.1007023.ref040" ref-type="bibr">40</xref>, <xref rid="pcbi.1007023.ref041" ref-type="bibr">41</xref>]. We have renamed the parameters of the original model for convenience. Note that both <italic>&#x003b1;</italic><sub><italic>R</italic></sub> and <italic>&#x003b7;</italic> influence the mutant contribution to &#x003bb;(<italic>w</italic>, <italic>m</italic>) (rather than the single parameter <italic>&#x003b4;</italic> in our linear model).</p></sec><sec id="sec019"><title>Expected cost per unit time</title><p>Let the cost per unit time of state (<italic>w</italic>, <italic>m</italic>) be denoted by <italic>C</italic>, and the cost corresponding to the steady state (<italic>w</italic><sub><italic>ss</italic></sub>, <italic>m</italic><sub><italic>ss</italic></sub>) by <inline-formula id="pcbi.1007023.e031"><alternatives><graphic xlink:href="pcbi.1007023.e031.jpg" id="pcbi.1007023.e031g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M31"><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover></mml:math></alternatives></inline-formula>. Even if steady state copy numbers are constant over time (i.e. the mean values of <italic>w</italic> and <italic>m</italic> are always equal to <italic>w</italic><sub><italic>ss</italic></sub> and <italic>m</italic><sub><italic>ss</italic></sub>) the mean cost per unit time is generally not equal to <inline-formula id="pcbi.1007023.e032"><alternatives><graphic xlink:href="pcbi.1007023.e032.jpg" id="pcbi.1007023.e032g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M32"><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover></mml:math></alternatives></inline-formula>. By performing a Taylor expansion, the mean cost per unit time can be written as follows:
<disp-formula id="pcbi.1007023.e033"><alternatives><graphic xlink:href="pcbi.1007023.e033.jpg" id="pcbi.1007023.e033g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M33"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>E</mml:mi><mml:mo>[</mml:mo><mml:mi>C</mml:mi><mml:mo>]</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo>(</mml:mo><mml:mtext>var</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi>&#x02202;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x02202;</mml:mi><mml:msup><mml:mi>w</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mtext>var</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi>&#x02202;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x02202;</mml:mi><mml:msup><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mtext>cov</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mi>&#x02202;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x02202;</mml:mi><mml:mi>w</mml:mi><mml:mi>&#x02202;</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(6)</label></disp-formula>
where <italic>E</italic>[<italic>C</italic>](<italic>t</italic>) is the expected cost per unit time given that the trajectory starts in state (<italic>w</italic><sub><italic>ss</italic></sub>, <italic>m</italic><sub><italic>ss</italic></sub>), and all partial derivatives are evaluated at steady state. These findings imply the following: suppose all cells in a population of cells are initialised in a state with minimum cost (corresponding to some specific number of mutant and wildtype mtDNA molecules). At some later time, the mtDNA populations in the different cells will have drifted apart and even if mean copy numbers (averaged over all cells) of <italic>w</italic> and <italic>m</italic> are identical to their initial values, the increase in variance between cells means that the overall mean cost (averaged over all cells) is higher than it was initially.</p></sec><sec id="sec020"><title>Cost function structure</title><p>We assume that the net energy supply per unit time in a state (<italic>w</italic>, <italic>m</italic>), called <italic>S</italic>(<italic>w</italic>, <italic>m</italic>), involves the following four terms: (i) the energy output per unit time (<italic>s</italic><sub><italic>i</italic></sub>) produced by the mitochondria; (ii) a maintenance cost per unit time (<italic>&#x003c1;</italic><sub>1</sub>) to maintain the mitochondria, as their presence imposes some energetic cost (e.g. mRNA and protein synthesis); (iii) a building cost (<italic>&#x003c1;</italic><sub>2</sub>) for the biogenesis of new mitochondria; and (iv) a degradation cost (<italic>&#x003c1;</italic><sub>3</sub>) to degrade mitochondria. We will assume that every mtDNA molecule is associated to a particular amount of mitochondrial volume which we refer to as a &#x02018;mitochondrion&#x02019; (section 4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>).</p><p>At any time, mitochondria experience a certain energy demand and to meet this demand they need to have a certain resource consumption rate <italic>r</italic><sub><italic>i</italic></sub> (where <italic>i</italic> = <italic>w</italic>, <italic>m</italic> refers to wildtype or mutant). Here we use the term &#x02018;resource&#x02019; as an amalgamation of the substrates used for the oxidation system. We need to specify the relationship between the power supply (<italic>s</italic>) and the rate of resources consumed (<italic>r</italic><sub><italic>i</italic></sub>) by mitochondria. We use two different models <italic>s</italic>(<italic>r</italic><sub><italic>i</italic></sub>) which are discussed further in section 3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>
<disp-formula id="pcbi.1007023.e034"><alternatives><graphic xlink:href="pcbi.1007023.e034.jpg" id="pcbi.1007023.e034g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M34"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>s</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mi>&#x003d5;</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>s</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mfrac><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>1</mml:mn><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(7)</label></disp-formula>
where <italic>&#x003d5;</italic>, <italic>&#x003b2;</italic>, <italic>k</italic> and <italic>s</italic><sub><italic>max</italic></sub> are constants respectively describing the mitochondrial efficiency, a basal proton leak-like term, the saturation rate of the efficiency, and the maximum power supply (section 4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>).</p><p>We assume that pathological mutants can have a deficient electron transport chain (which may support a smaller flux leading to a lower resource consumption rate for mutants and therefore a lower ATP production rate) and a lower energy production efficiency, leading to the following mutant energy output: <italic>&#x003f5;</italic><sub>2</sub><italic>s</italic>(<italic>&#x003f5;</italic><sub>1</sub><italic>r</italic><sub><italic>w</italic></sub>). Here, <italic>&#x003f5;</italic><sub>1</sub>, <italic>&#x003f5;</italic><sub>2</sub> &#x02208; [0, 1] describe the mutant resource uptake rate and the mutant energy production efficiency relative to that of a wildtype, respectively. In the main text we set <italic>&#x003f5;</italic><sub>2</sub> = 1; other values of <italic>&#x003f5;</italic><sub>2</sub> are discussed in section 4.7 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>.</p><p>The mitochondrial maintenance cost is denoted by <italic>&#x003c1;</italic><sub>1</sub> and corresponds to the energetic cost required to maintain the mitochondrion that contains the mtDNA. This energetic costs involves factors like the synthesis and degradation of mitochondrial proteins and enzymes. We assume the maintenance cost is the same for wildtype and mutant mitochondria (though for some mutations this is quite possibly not the case). The net energy supply per unit time, <italic>S</italic>(<italic>w</italic>, <italic>m</italic>), then follows as <xref ref-type="disp-formula" rid="pcbi.1007023.e015">Eq 3</xref>.</p><p>To determine the value of <italic>r</italic><sub><italic>w</italic></sub> for a given state (<italic>w</italic>, <italic>m</italic>), we first check whether the demand <italic>D</italic> (which we assume is a constant) can be satisfied by supply <italic>S</italic>(<italic>w</italic>, <italic>m</italic>). If it can, we set <xref ref-type="disp-formula" rid="pcbi.1007023.e015">Eq (3)</xref> equal to <italic>D</italic> and solve for <italic>r</italic><sub><italic>w</italic></sub>, i.e. we assume that if possible, the mitochondria will exactly satisfy demand. It may, however, not be possible to satisfy demand, which can be because of two reasons: i) there are not enough mitochondria present to produce enough energy, or ii) the resource supply rate, <italic>R</italic> (a constant), is not enough to meet demand. In the former case, we set <italic>r</italic><sub><italic>w</italic></sub> = <italic>r</italic><sub><italic>max</italic></sub> (a specified maximum resource consumption rate per mitochondrion): the mitochondria work as hard as possible to keep their energy output closest to demand. In the latter case, we assume that the total available resource supply is shared equally between the mitochondria: <inline-formula id="pcbi.1007023.e035"><alternatives><graphic xlink:href="pcbi.1007023.e035.jpg" id="pcbi.1007023.e035g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M35"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mi>R</mml:mi><mml:mrow><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>m</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula>. Further details of the cost function are given in sections 3&#x02013;5 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>.</p><p>The parameters used in our cost function are summarised in <xref ref-type="supplementary-material" rid="pcbi.1007023.s013">S2 Table</xref> and motivated in section 4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. Despite our model being simple, most parameters are biologically interpretable.</p></sec><sec id="sec021"><title>Modelling control through mitochondrially targeted endonucleases</title><p>Experimentally, cells are transfected with two mtZFN monomers: one which binds selectively to mutant mtDNAs, and one that binds mutants and wildtypes with equal strength [<xref rid="pcbi.1007023.ref062" ref-type="bibr">62</xref>]. We simplify this picture by assuming an &#x02018;effective&#x02019; mtZFN pool and use [<italic>ZFN</italic>] to denote its concentration. The increase in mtDNA degradation rate caused by the mtZFNs is then assumed to be proportional to [<italic>ZFN</italic>].</p><p>Nucleases are imported into the cell and then degrade over time, meaning that their concentration in the cell (and in the mitochondria) may be approximated by an immigration-death model:
<disp-formula id="pcbi.1007023.e036"><alternatives><graphic xlink:href="pcbi.1007023.e036.jpg" id="pcbi.1007023.e036g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M36"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mo>[</mml:mo><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>]</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mi>z</mml:mi></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(8)</label></disp-formula>
where <italic>I</italic>(<italic>t</italic>) and <italic>&#x003bc;</italic><sub><italic>Z</italic></sub> are the immigration and death rates of the effective mtZFN pool, respectively. In recent experiments [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>], nucleases are expressed for short times meaning that the immigration rate will increase sharply at the start of the treatment after which it decreases over time: we chose to model <italic>I</italic>(<italic>t</italic>) as an exponentially decaying function, <italic>I</italic>(<italic>t</italic>) = <italic>I</italic><sub>0</sub><italic>e</italic><sup>&#x02212;<italic>bt</italic></sup>, where <italic>I</italic><sub>0</sub> denotes the initial rate directly after the treatment is initiated and <italic>b</italic> is a constant describing the duration of the treatment. The mtZFN concentration now becomes
<disp-formula id="pcbi.1007023.e037"><alternatives><graphic xlink:href="pcbi.1007023.e037.jpg" id="pcbi.1007023.e037g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M37"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>I</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mi>z</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mi>b</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mi>z</mml:mi></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(9)</label></disp-formula>
which is shown for various parameter values in <xref ref-type="supplementary-material" rid="pcbi.1007023.s008">S8A Fig</xref>. The data we use to fit our models concerns heteroplasmy and total copy number measurements over four rounds of treatment, each treatment consisting of mtZFN transfection followed by a 28-day recovery period. During this recovery period, total copy numbers recover their initial values due to cellular feedback control. The increase in mtDNA death rate due to the presence of the mtZFNs, <italic>&#x003bc;</italic><sub><italic>ZFN</italic></sub>, is given by
<disp-formula id="pcbi.1007023.e038"><alternatives><graphic xlink:href="pcbi.1007023.e038.jpg" id="pcbi.1007023.e038g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M38"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mn>28</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>28</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>+</mml:mo><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:munderover><mml:mrow><mml:mo>[</mml:mo><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>28</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(10)</label></disp-formula>
where <italic>i</italic> = 0, 1, 2, 3 indicates the treatment round. This equation is simply stating that new mtZFNs are added every 28 days. Death rates for <italic>m</italic> and <italic>w</italic> are now assumed to be
<disp-formula id="pcbi.1007023.e039"><alternatives><graphic xlink:href="pcbi.1007023.e039.jpg" id="pcbi.1007023.e039g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M39"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>&#x003bc;</mml:mi><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>w</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003be;</mml:mi><mml:mo>&#x000b7;</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>&#x003bc;</mml:mi><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(11)</label></disp-formula>
where <italic>&#x003bc;</italic> denotes the baseline degradation rate and <italic>&#x003be;</italic> represents treatment selectivity (e.g. when <italic>&#x003be;</italic> = 0 there is no off-target cleavage).</p></sec><sec id="sec022"><title>Model fits using Metropolis sampling</title><p>To fit our nuclease model to recently obtained experimental data [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>], we use <xref ref-type="disp-formula" rid="pcbi.1007023.e029">Eq (4)</xref> with <italic>&#x003bc;</italic> replaced by <italic>&#x003bc;</italic>(<italic>t</italic>)<sub><italic>w</italic></sub> or <italic>&#x003bc;</italic>(<italic>t</italic>)<sub><italic>m</italic></sub> and &#x003bb;(<italic>w</italic>, <italic>m</italic>) given by <xref ref-type="disp-formula" rid="pcbi.1007023.e001">Eq (1)</xref>:
<disp-formula id="pcbi.1007023.e040"><alternatives><graphic xlink:href="pcbi.1007023.e040.jpg" id="pcbi.1007023.e040g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M40"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mi>w</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b4;</mml:mi><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mi>&#x003be;</mml:mi><mml:mo>&#x000b7;</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:mi>m</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b4;</mml:mi><mml:mi>m</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(12)</label></disp-formula></p><p>Total mtDNA copy numbers in pre-treatment 80% heteroplasmy cells were measured using quantitative PCR (section 6.4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>) and were found to be 889 &#x000b1; 214 (S.E., <italic>n</italic> = 3). We therefore assume an initial total copy number of 900, meaning <italic>w</italic> and <italic>m</italic> were initialized at 0.2 &#x022c5; 900 = 180 and 0.8 &#x022c5; 900 = 720, respectively. These evolution equations incorporate cellular feedback control as well as the nuclease treatment which occurs in cycles of 28 days. The mtZFN degradation rate was assumed to be <italic>&#x003bc;</italic><sub><italic>z</italic></sub> = ln(2) day<sup>&#x02212;1</sup>, corresponding to a half-life of 1 day. This is in accord with the experimental observation that almost no mtZFN was present 4 days post-transfection (with a half-life of 1 day, only 6% of initial copy numbers remain after 4 days).</p><p>MCMC inference was performed using the Python package Pymc3, a package designed for Bayesian statistical modelling and probabilistic machine learning [<xref rid="pcbi.1007023.ref094" ref-type="bibr">94</xref>]. A Gaussian error model was assumed, i.e. the observed heteroplasmy <inline-formula id="pcbi.1007023.e041"><alternatives><graphic xlink:href="pcbi.1007023.e041.jpg" id="pcbi.1007023.e041g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M41"><mml:msubsup><mml:mi>y</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>h</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> and total copy number <inline-formula id="pcbi.1007023.e042"><alternatives><graphic xlink:href="pcbi.1007023.e042.jpg" id="pcbi.1007023.e042g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M42"><mml:msubsup><mml:mi>y</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> data are given by
<disp-formula id="pcbi.1007023.e043"><alternatives><graphic xlink:href="pcbi.1007023.e043.jpg" id="pcbi.1007023.e043g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M43"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:msubsup><mml:mi>y</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>h</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>h</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mi>h</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:msubsup><mml:mi>y</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(13)</label></disp-formula>
where <inline-formula id="pcbi.1007023.e044"><alternatives><graphic xlink:href="pcbi.1007023.e044.jpg" id="pcbi.1007023.e044g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M44"><mml:msubsup><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>h</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1007023.e045"><alternatives><graphic xlink:href="pcbi.1007023.e045.jpg" id="pcbi.1007023.e045g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M45"><mml:msubsup><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> denote our predicted heteroplasmy and copy number values obtained by numerically solving <xref ref-type="disp-formula" rid="pcbi.1007023.e040">Eq (12)</xref>, and we allow for different noise variances for <italic>h</italic> and <italic>T</italic> (in general, different experimental errors are expected as different methods are used to measure <italic>h</italic> and <italic>T</italic>). A metropolis sampler is used for parameter estimation. Maximum a posteriori (MAP) values were found to be <inline-formula id="pcbi.1007023.e046"><alternatives><graphic xlink:href="pcbi.1007023.e046.jpg" id="pcbi.1007023.e046g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M46"><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>&#x003be;</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x003b4;</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mi>h</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>A</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02248;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>122</mml:mn><mml:mo>.</mml:mo><mml:mn>82</mml:mn><mml:mo>,</mml:mo><mml:mn>46</mml:mn><mml:mo>.</mml:mo><mml:mn>68</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>90</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>72</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>26</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>061</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>10</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>. Due to a degeneracy in our mtZFN dynamics model (section 6.5 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>) the MAP values of <italic>I</italic><sub>0</sub> and <italic>b</italic> are not necessarily unique at large <italic>b</italic> (details in section 6.5 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>).</p><p>We explore the ability of our model to account for additional data from Ref. [<xref rid="pcbi.1007023.ref036" ref-type="bibr">36</xref>] (<xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5C and 5D</xref>) which was not included in our inference. Using the MAP values for parameters <italic>I</italic><sub>0</sub>, <italic>b</italic>, <italic>c</italic><sub>1</sub>, <italic>&#x003b4;</italic>, <inline-formula id="pcbi.1007023.e047"><alternatives><graphic xlink:href="pcbi.1007023.e047.jpg" id="pcbi.1007023.e047g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M47"><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mi>h</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1007023.e048"><alternatives><graphic xlink:href="pcbi.1007023.e048.jpg" id="pcbi.1007023.e048g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M48"><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math></alternatives></inline-formula> (based on the data shown in <xref ref-type="fig" rid="pcbi.1007023.g005">Fig 5A and 5B</xref>), the maximum likelihood estimate of <italic>&#x003be;</italic> is obtained based on the additional data, using a Gaussian error model similar to <xref ref-type="disp-formula" rid="pcbi.1007023.e043">Eq (13)</xref>. This maximum likelihood value is <italic>&#x003be;</italic> &#x02248; 0.15.</p></sec></sec><sec sec-type="supplementary-material" id="sec023"><title>Supporting information</title><supplementary-material content-type="local-data" id="pcbi.1007023.s001"><label>S1 Fig</label><caption><title>A linear feedback control has straight steady state lines.</title><p><bold>A)</bold> The deterministic steady state lines of the feedback control given in <xref ref-type="disp-formula" rid="pcbi.1007023.e029">Eq 4</xref>, using our linear version of &#x003bb;(<italic>w</italic>, <italic>m</italic>), are shown in (<italic>w</italic>, <italic>m</italic>) space for various values of <italic>&#x003b4;</italic> (grey lines show particular examples of ranges of <italic>&#x003b4;</italic>). Constant heteroplasmy lines form straight lines through the origin. <bold>B, C, D) Equal variances for different feedback control mechanisms</bold>. Three different controls (see legend), all of the form &#x003bb;(<italic>w</italic> + <italic>&#x003b4;m</italic>) with <italic>&#x003b4;</italic> = 0.5, show nearly identical wildtype, mutant and heteroplasmy variances. Other parameters used are <italic>N</italic><sub><italic>ss</italic></sub> = 1000 (referring to the steady state copy number present in the absence of mutants), <italic>&#x003bc;</italic> = 0.07 (corresponding to a half-life of 10 days), and initial copy numbers (<italic>w</italic><sub>0</sub>, <italic>m</italic><sub>0</sub>) = (920, 160) (corresponding to an initial heteroplasmy of &#x0223c; 0.15).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s001.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s002"><label>S2 Fig</label><caption><title>Relationship between resource consumption and energy output.</title><p><bold>A)</bold> The energy production rate of a single wildtype mitochondrion as a function of its resource consumption rate is shown, as given by Eqs. (15) and (16) in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. For the linear model (corresponding to the straight lines) the parameters <italic>&#x003d5;</italic> and <italic>&#x003b2;</italic> are changed by 10%, for the saturating model we vary <italic>s</italic><sub><italic>max</italic></sub> and <italic>k</italic>. The magenta line indicates <italic>r</italic><sub><italic>max</italic></sub>. <bold>B)</bold> As <italic>w</italic> increases, demand is shared between more mitochondria and each individual one can afford to consume resources at a lower rate (the same figure legend applies for figures C, D and E). <bold>C)</bold> The total resource consumption increases with <italic>w</italic> because the mitochondria need to consume a non-zero amount of resources to produce a net energy output and each mitochondrion comes with a maintenance cost. <bold>D)</bold> The total energy produced by wildtypes increases when mutants are present. <bold>E)</bold> When demand is satisfied, the cost increases with <italic>w</italic> in the linear model, resulting in minimal costs when copy numbers attain the minimum number required to satisfy demand (1). In contrast, for the saturating model the cost decreases at first because as individual resource consumption drops, the energy production efficiency increases. Minimum cost now occurs when mitochondria are working most efficiently (2). Parameters <italic>&#x003f5;</italic><sub>1</sub> = 0.1 and <italic>&#x003f5;</italic><sub>2</sub> = 1.0 were used.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s002.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s003"><label>S3 Fig</label><caption><title>Changing mutant efficiency (<italic>&#x003f5;</italic><sub>2</sub>) does not lead to expensive intermediate heteroplasmies.</title><p><bold>A), B)</bold> Similar to <xref ref-type="fig" rid="pcbi.1007023.g002">Fig 2</xref> in the main text, these figures show the cost values in (<italic>w</italic>, <italic>m</italic>) space, but now as a function of <italic>&#x003f5;</italic><sub>2</sub> (mutant efficiency) instead of <italic>&#x003f5;</italic><sub>1</sub>. This time we show the cost in the entire space. The white lines show the region in which demand is satisfied for our default parameter values. Because mutants consume the same amount of resource as wildtypes (<italic>&#x003f5;</italic><sub>1</sub> = 1), resource becomes limiting at relatively low values of <italic>m</italic> compared to when <italic>&#x003f5;</italic><sub>1</sub> &#x0003c; 1. Note that intermediate heteroplasmies are not less efficient here.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s003.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s004"><label>S4 Fig</label><caption><title>Intermediate h values require more resources to satisfy demand, but only if mutants consume less resources.</title><p><bold>A)</bold> The resource consumption rates and energy production rates of wildtypes and mutants are shown for two states: (<italic>w</italic><sub>1</sub>, <italic>m</italic><sub>1</sub>, <italic>h</italic><sub>1</sub>) = (9000, 1000, 0.1) and (<italic>w</italic><sub>2</sub>, <italic>m</italic><sub>2</sub>, <italic>h</italic><sub>2</sub>) = (7000, 3000, 0.3). In both cases, the total energy output is equal to the demand. When heteroplasmy is higher (<italic>h</italic> = 0.3), the individual resource consumption rates are higher in order to maintain a constant total energy output. Overall, the state with <italic>h</italic> = 0.1 uses the least resources (Eq. (20) in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). <italic>&#x003f5;</italic><sub>1</sub> = 0.35 was used. <bold>B)</bold> This figure is similar to figure (D) but now the two states (<italic>w</italic><sub>1</sub>, <italic>m</italic><sub>1</sub>, <italic>h</italic><sub>1</sub>) = (3000, 7000, 0.7) and (<italic>w</italic><sub>2</sub>, <italic>m</italic><sub>2</sub>, <italic>h</italic><sub>2</sub>) = (1000, 9000, 0.9) are compared. The state with <italic>h</italic> = 0.9 uses the least resources (Eq. (21) in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s004.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s005"><label>S5 Fig</label><caption><title>The existence of intermediate heteroplasmy values is a robust feature of the saturating output model.</title><p>We show the value of <italic>h</italic><sub><italic>max</italic></sub>, the most expensive heteroplasmy value at constant copy number, as a function of total copy number and <italic>&#x003f5;</italic><sub>1</sub> (describing mutant pathology). White regions correspond to <italic>h</italic><sub><italic>max</italic></sub> = 1. <bold>A)</bold> Using our default parameter values, an intermediate <italic>h</italic><sub><italic>max</italic></sub> exists for large enough mutant functionality <italic>&#x003f5;</italic><sub>1</sub>. <bold>B)</bold> The parameter <italic>s</italic><sub><italic>max</italic></sub> is increased by 50% with minimal effect on the output. We kept the parameter <italic>k</italic> fixed as it defines the amount of proton leak (the resource consumption rate at zero energy output) which agrees with the amount of proton leak in the linear output model whose parameters are based on experimental data. <bold>C)</bold> The parameter <italic>&#x003c1;</italic><sub>1</sub> is increased by an order of magnitude with minimal effect on the output. <bold>D)</bold> The parameter <italic>&#x003c1;</italic><sub>1</sub> is increased by an order of magnitude and <italic>s</italic><sub><italic>max</italic></sub> is decreased by 50%. Again, change in <italic>h</italic><sub><italic>max</italic></sub> are small.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s005.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s006"><label>S6 Fig</label><caption><title>Wildtype, mutant and cost dynamics for four different control strategies.</title><p>Dynamics are shown for the four controls I, II, III, and IV defined in Table 3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. Again, we see that the effects of the control are more noticeable in low copy number cells. Parameters are set as given in Table 3 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. Values for <italic>w</italic><sub><italic>opt</italic></sub> are those for the saturating output model at low and high copy number. The free parameters in control III and IV (<italic>&#x003b4;</italic> and <italic>&#x003b7;</italic>) were optimised over initial conditions in the range <italic>h</italic> &#x02208; [0, 0.2]. For the optimization the default cost function parameters were used as well as <italic>&#x003f5;</italic><sub>1</sub> = 0.3.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s006.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s007"><label>S7 Fig</label><caption><title>At long times and high heteroplasmies, energy sensing control becomes suboptimal.</title><p>The optimal value of <italic>&#x003b4;</italic> in a linear feedback control is shown as a function of <italic>&#x003f5;</italic><sub>1</sub>. Here we used <italic>T</italic> = 10<sup>4</sup> days (optimization time) and low copy numbers for both the linear and saturating model. The solid and dashed lines correspond to trajectories starting at <italic>h</italic><sub>0</sub> = 0.1 and <italic>h</italic><sub>0</sub> = 0.8, respectively. The less resources the mutants consume (and the less output they therefore produce) the lower their optimal contribution to the control.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s007.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s008"><label>S8 Fig</label><caption><title>Zinc finger nuclease concentrations for short and long treatments.</title><p><bold>A)</bold> Here we show the concentration of mitochondrially targeted Zinc Fingers as modelled by <xref ref-type="disp-formula" rid="pcbi.1007023.e037">Eq (9)</xref> in the main text. The parameter values for the short and strong treatment illustrated here (<italic>I</italic><sub>0</sub> = 36, <italic>b</italic> = 11) are similar to those found in fitting the model to the data. For the mtZFN degradation rate we used <italic>&#x003bc;</italic><sub><italic>Z</italic></sub> = log(2) day<sup>&#x02212;1</sup> (corresponding to a mtZFN half-life of 1 day). <bold>There exists a possibility of increasing heteroplasmy levels through treatment</bold>. <bold>B)</bold> The probability of increasing heteroplasmy above its initial pre-treatment value <italic>h</italic><sub>0</sub>, after one round of treatment and recovery, is shown as a function of <italic>h</italic><sub>0</sub> and <italic>&#x003be;</italic>. Cells are initialised with a total copy number of 500. The cross indicates the parameters used in figure (D). The parameter values for <italic>I</italic><sub>0</sub>, <italic>b</italic> and <italic>c</italic><sub>1</sub> are fixed at: (<italic>I</italic><sub>0</sub>, <italic>b</italic>, <italic>c</italic><sub>1</sub>) &#x02248; (39, 20, 3 &#x000d7; 10<sup>&#x02212;4</sup>); these values provide good fits to experimental data when assuming a total initial copy number of 500. We used <italic>&#x003b4;</italic> = 1. <bold>C)</bold> Similar to figure (B), but now cells are initialised with a total copy number of 5000; in these large copy number cells stochastic fluctuations in copy number have less effect and the probabilities of exceeding initial heteroplasmy values are smaller compared to figure (B). <bold>D)</bold> An example of a distribution of post-treatment heteroplasmy values is shown using parameters <italic>h</italic><sub>0</sub> and <italic>&#x003be;</italic> as indicated by the cross in figure (B). The orange line indicates the value of <italic>h</italic><sub>0</sub> (the heteroplasmy that was present before the treatment started).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s008.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s009"><label>S9 Fig</label><caption><title>mtZFN expression profile during transient transfection of 143B cells.</title><p><bold>A)</bold> Here we show a schematic of the experiments involving i) transient transfection of high-heteroplasmy cells with plasmids expressing mtZFN monomers and fluorescent marker proteins, ii) FACS-based selection of cells expressing both mtZFN monomers (NARPd(+) and COMPa(-)), and iii) phenotypic evaluation of treated cells. Technical details are provided in Ref. [<xref rid="pcbi.1007023.ref035" ref-type="bibr">35</xref>]. <bold>B)</bold> Western blots showing the mtZFN expression profile indicate that the mtZFNs are almost undetectable at 96 hours post-transfection, and completely undetectable at 120 hours. Details of the protocol are provided in Ref. [<xref rid="pcbi.1007023.ref035" ref-type="bibr">35</xref>].</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s009.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s010"><label>S10 Fig</label><caption><title>Posterior mtZFN treatment parameter distributions.</title><p>Here we show our posterior distributions obtained after running our MCMC algorithm (left) as well as the corresponding sample values (right). Prior distributions are provided in the text. The posterior of log<sub>10</sub>
<italic>b</italic> is cut off due to a degeneracy in our model (Eq. (22) in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>), which does not affect our model predictions.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s010.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s011"><label>S11 Fig</label><caption><title>Predictions of mtZFN expression are broadly consonant with experimental data.</title><p>Drawing from our posterior distributions for <italic>I</italic><sub>0</sub> and <italic>b</italic> obtained through Metropolis sampling, we show 50% and 95% credible intervals of our predicted mtZFN expression profile (solid black line denotes the maximum a posteriori (MAP) estimate). Data points are obtained through quantification of the western blots shown in <xref ref-type="supplementary-material" rid="pcbi.1007023.s009">S9B Fig</xref> and were subsequently rescaled to investigate whether our model can broadly account for the experimentally observed dynamics (our predicted mtZFN concentrations are proportional to the measurement data points with an arbitrary proportionality constant).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s011.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s012"><label>S1 Table</label><caption><title>Analytical expressions for the means and variances according to the linear noise approximation.</title><p>Solutions are shown for wildtype, mutant, and heteroplasmy variances for various types of control. Dots indicate constant or exponentially decaying terms; full solutions are provided in Eqs. (11)&#x02013;(13) in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. Note that the initial rate of increase of heteroplasmy variance only depends on mtDNA copy number and turnover (see also [<xref rid="pcbi.1007023.ref038" ref-type="bibr">38</xref>]).</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s012.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s013"><label>S2 Table</label><caption><title>Parameters used in our mitochondrial cost function with their descriptions.</title><p>Parameter values are derived and motivated in Section 4 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>. In this table, &#x02018;high&#x02019; and &#x02018;low&#x02019; refer to high and low copy numbers, respectively, and the abbreviations &#x02018;sat.&#x02019; and &#x02018;lin.&#x02019; are used to indicate our saturating and linear output models.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s013.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s014"><label>S3 Table</label><caption><title>Parameter values for the four different control mechanisms we employ.</title><p>Two parameters of each control are set by the two constraints we impose. The parameter <italic>&#x003b1;</italic><sub><italic>R</italic></sub> was proposed to lie in the range 5-17 [<xref rid="pcbi.1007023.ref040" ref-type="bibr">40</xref>] and here we used <italic>&#x003b1;</italic><sub><italic>R</italic></sub> = 10. The values for <italic>&#x003b4;</italic> and <italic>&#x003b7;</italic> are found by optimizing our cost function over the steady states corresponding to our initial conditions. We used 50 initial conditions equally spread over the range <italic>h</italic><sub>0</sub> &#x02208; [0, 0.2]. The two values used for <italic>w</italic><sub><italic>opt</italic></sub> are 1524 and 7616 (Table 2 in <xref ref-type="supplementary-material" rid="pcbi.1007023.s015">S1 File</xref>). We further use <italic>&#x003bc;</italic> = 0.07 day<sup>&#x02212;1</sup>.</p><p>(EPS)</p></caption><media xlink:href="pcbi.1007023.s014.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1007023.s015"><label>S1 File</label><caption><title>Supporting text.</title><p>(PDF)</p></caption><media xlink:href="pcbi.1007023.s015.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pcbi.1007023.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Laar</surname><given-names>V. S. V.</given-names></name> and <name><surname>Berman</surname><given-names>S. B</given-names></name>. <article-title>Mitochondrial dynamics in parkinson&#x02019;s disease</article-title>. <source><italic toggle="yes">Exp Neurol</italic></source>
<volume>218</volume>(<issue>2</issue>), <fpage>247</fpage>&#x02013;<lpage>256</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1016/j.expneurol.2009.03.019</pub-id>
<?supplied-pmid 19332061?><pub-id pub-id-type="pmid">19332061</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Liesa</surname><given-names>M.</given-names></name>, <name><surname>Palac&#x000ed;n</surname><given-names>M.</given-names></name>, and <name><surname>Zorzano</surname><given-names>A</given-names></name>. <article-title>Mitochondrial dynamics in mammalian health and disease</article-title>. <source><italic toggle="yes">Physiol Rev</italic></source>
<volume>89</volume>(<issue>3</issue>), <fpage>799</fpage>&#x02013;<lpage>845</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1152/physrev.00030.2008</pub-id>
<?supplied-pmid 19584314?><pub-id pub-id-type="pmid">19584314</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Grandemange</surname><given-names>S.</given-names></name>, <name><surname>Herzig</surname><given-names>S.</given-names></name>, and <name><surname>Martinou</surname><given-names>J.-C</given-names></name>. <article-title>Mitochondrial dynamics and cancer</article-title>. <source><italic toggle="yes">Semin Cancer Biol</italic></source>
<volume>19</volume>(<issue>1</issue>), <fpage>50</fpage>&#x02013;<lpage>56</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1016/j.semcancer.2008.12.001</pub-id>
<?supplied-pmid 19138741?><pub-id pub-id-type="pmid">19138741</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Zhu</surname><given-names>X.</given-names></name>, <name><surname>Perry</surname><given-names>G.</given-names></name>, <name><surname>Smith</surname><given-names>M. A.</given-names></name>, and <name><surname>Wang</surname><given-names>X</given-names></name>. <article-title>Abnormal mitochondrial dynamics in the pathogenesis of alzheimer&#x02019;s disease</article-title>. <source><italic toggle="yes">J Alzheimers Dis</italic></source>
<volume>33</volume>, <fpage>S253</fpage>&#x02013;<lpage>S262</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.3233/JAD-2012-129005</pub-id>
<?supplied-pmid 22531428?><pub-id pub-id-type="pmid">22531428</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Chan</surname><given-names>D. C</given-names></name>. <article-title>Fusion and fission: Interlinked processes critical for mitochondrial health</article-title>. <source><italic toggle="yes">Annu Rev Genet</italic></source>
<volume>46</volume>(<issue>1</issue>), <fpage>265</fpage>&#x02013;<lpage>287</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1146/annurev-genet-110410-132529</pub-id>
<?supplied-pmid 22934639?><pub-id pub-id-type="pmid">22934639</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>H.</given-names></name> and <name><surname>Chan</surname><given-names>D. C.</given-names></name>
<article-title>Mitochondrial dynamics&#x02014;fusion, fission, movement, and mitophagy&#x02014;in neurodegenerative diseases</article-title>. <source><italic toggle="yes">Hum Mol Genet</italic></source>
<volume>18</volume>(<issue>R2</issue>), <fpage>R169</fpage>&#x02013;<lpage>R176</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1093/hmg/ddp326</pub-id>
<?supplied-pmid 19808793?><pub-id pub-id-type="pmid">19808793</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Hayashi</surname><given-names>J.-L.</given-names></name>, <name><surname>Ohta</surname><given-names>S.</given-names></name>, <name><surname>Kikuchi</surname><given-names>A.</given-names></name>, <name><surname>Takemitsu</surname><given-names>M.</given-names></name>, <name><surname>Goto</surname><given-names>Y.-i.</given-names></name>, and <name><surname>Nonaka</surname><given-names>I</given-names></name>. <article-title>Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source>
<volume>88</volume>(<issue>23</issue>), <fpage>10614</fpage>&#x02013;<lpage>10618</lpage> (<year>1991</year>). <pub-id pub-id-type="doi">10.1073/pnas.88.23.10614</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Rossignol</surname><given-names>R.</given-names></name>, <name><surname>Faustin</surname><given-names>B.</given-names></name>, <name><surname>Rocher</surname><given-names>C.</given-names></name>, <name><surname>Malgat</surname><given-names>M.</given-names></name>, <name><surname>Mazat</surname><given-names>J.-P.</given-names></name>, and <name><surname>Letellier</surname><given-names>T</given-names></name>. <article-title>Mitochondrial threshold effects</article-title>. <source><italic toggle="yes">Biochemical Journal</italic></source>
<volume>370</volume>(<issue>3</issue>), <fpage>751</fpage>&#x02013;<lpage>762</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1042/BJ20021594</pub-id>
<?supplied-pmid 12467494?><pub-id pub-id-type="pmid">12467494</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Attardi</surname><given-names>G.</given-names></name>, <name><surname>Yoneda</surname><given-names>M.</given-names></name>, and <name><surname>Chomyn</surname><given-names>A</given-names></name>. <article-title>Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems</article-title>. <source><italic toggle="yes">Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease</italic></source>
<volume>1271</volume>(<issue>1</issue>), <fpage>241</fpage>&#x02013;<lpage>248</lpage> (<year>1995</year>). <pub-id pub-id-type="doi">10.1016/0925-4439(95)00034-2</pub-id><pub-id pub-id-type="pmid">7599215</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Boulet</surname><given-names>L.</given-names></name>, <name><surname>Karpati</surname><given-names>G.</given-names></name>, and <name><surname>Shoubridge</surname><given-names>E</given-names></name>. <article-title>Distribution and threshold expression of the tRNA (Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF)</article-title>. <source><italic toggle="yes">American journal of human genetics</italic></source>
<volume>51</volume>(<issue>6</issue>), <fpage>1187</fpage> (<year>1992</year>). <?supplied-pmid 1334369?><pub-id pub-id-type="pmid">1334369</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Nakada</surname><given-names>K.</given-names></name>, <name><surname>Inoue</surname><given-names>K.</given-names></name>, <name><surname>Ono</surname><given-names>T.</given-names></name>, <name><surname>Isobe</surname><given-names>K.</given-names></name>, <name><surname>Ogura</surname><given-names>A.</given-names></name>, <name><surname>Goto</surname><given-names>Y.-i.</given-names></name>, <name><surname>Nonaka</surname><given-names>I.</given-names></name>, and <name><surname>Hayashi</surname><given-names>J.-I.</given-names></name>
<article-title>Inter-mitochondrial complementation: mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA</article-title>. <source><italic toggle="yes">Nature medicine</italic></source>
<volume>7</volume>(<issue>8</issue>), <fpage>934</fpage>&#x02013;<lpage>940</lpage> (<year>2001</year>). <pub-id pub-id-type="doi">10.1038/90976</pub-id>
<?supplied-pmid 11479626?><pub-id pub-id-type="pmid">11479626</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Moraes</surname><given-names>C. T.</given-names></name> and <name><surname>Schon</surname><given-names>E. A.</given-names></name>
<article-title>[44] detection and analysis of mitochondrial DNA and RNA in muscle by in situ hybridization and single-fiber pcr</article-title>. <source><italic toggle="yes">Methods in enzymology</italic></source>
<volume>264</volume>, <fpage>522</fpage>&#x02013;<lpage>540</lpage> (<year>1996</year>). <pub-id pub-id-type="doi">10.1016/S0076-6879(96)64046-4</pub-id><pub-id pub-id-type="pmid">8965724</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Sciacco</surname><given-names>M.</given-names></name>, <name><surname>Bonilla</surname><given-names>E.</given-names></name>, <name><surname>Schon</surname><given-names>E. A.</given-names></name>, <name><surname>DiMauro</surname><given-names>S.</given-names></name>, and <name><surname>Moraes</surname><given-names>C. T</given-names></name>. <article-title>Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy</article-title>. <source><italic toggle="yes">Human Molecular Genetics</italic></source>
<volume>3</volume>(<issue>1</issue>), <fpage>13</fpage>&#x02013;<lpage>19</lpage> (<year>1994</year>). <pub-id pub-id-type="doi">10.1093/hmg/3.1.13</pub-id>
<?supplied-pmid 8162014?><pub-id pub-id-type="pmid">8162014</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Russell</surname><given-names>O.</given-names></name> and <name><surname>Turnbull</surname><given-names>D.</given-names></name>
<article-title>Mitochondrial DNA disease&#x02014;molecular insights and potential routes to a cure</article-title>. <source><italic toggle="yes">Experimental cell research</italic></source>
<volume>325</volume>(<issue>1</issue>), <fpage>38</fpage>&#x02013;<lpage>43</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1016/j.yexcr.2014.03.012</pub-id>
<?supplied-pmid 24675282?><pub-id pub-id-type="pmid">24675282</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Durham</surname><given-names>S. E.</given-names></name>, <name><surname>Samuels</surname><given-names>D. C.</given-names></name>, <name><surname>Cree</surname><given-names>L. M.</given-names></name>, and <name><surname>Chinnery</surname><given-names>P. F</given-names></name>. <article-title>Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m. 3243a&#x02192; g</article-title>. <source><italic toggle="yes">The American Journal of Human Genetics</italic></source>
<volume>81</volume>(<issue>1</issue>), <fpage>189</fpage>&#x02013;<lpage>195</lpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1086/518901</pub-id>
<?supplied-pmid 17564976?><pub-id pub-id-type="pmid">17564976</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref016"><label>16</label><mixed-citation publication-type="other">Gitschlag B. L., Kirby C. S., Samuels D. C., Gangula R. D., Mallal S. A., and Patel M. R. Homeostatic responses regulate selfish mitochondrial genome dynamics in c. elegans. <italic>bioRxiv</italic>, 050930 (2016).</mixed-citation></ref><ref id="pcbi.1007023.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Posakony</surname><given-names>J. W.</given-names></name>, <name><surname>England</surname><given-names>J. M.</given-names></name>, and <name><surname>Attardi</surname><given-names>G</given-names></name>. <article-title>Mitochondrial growth and division during the cell cycle in hela cells</article-title>. <source><italic toggle="yes">The Journal of cell biology</italic></source>
<volume>74</volume>(<issue>2</issue>), <fpage>468</fpage>&#x02013;<lpage>491</lpage> (<year>1977</year>). <pub-id pub-id-type="doi">10.1083/jcb.74.2.468</pub-id>
<?supplied-pmid 885911?><pub-id pub-id-type="pmid">885911</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Jajoo</surname><given-names>R.</given-names></name>, <name><surname>Jung</surname><given-names>Y.</given-names></name>, <name><surname>Huh</surname><given-names>D.</given-names></name>, <name><surname>Viana</surname><given-names>M. P.</given-names></name>, <name><surname>Rafelski</surname><given-names>S. M.</given-names></name>, <name><surname>Springer</surname><given-names>M.</given-names></name>, and <name><surname>Paulsson</surname><given-names>J</given-names></name>. <article-title>Accurate concentration control of mitochondria and nucleoids</article-title>. <source><italic toggle="yes">Science</italic></source>
<volume>351</volume> (<issue>6269</issue>), <fpage>169</fpage>&#x02013;<lpage>172</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1126/science.aaa8714</pub-id>
<?supplied-pmid 26744405?><pub-id pub-id-type="pmid">26744405</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Otten</surname><given-names>A. B.</given-names></name>, <name><surname>Theunissen</surname><given-names>T. E.</given-names></name>, <name><surname>Derhaag</surname><given-names>J. G.</given-names></name>, <name><surname>Lambrichs</surname><given-names>E. H.</given-names></name>, <name><surname>Boesten</surname><given-names>I. B.</given-names></name>, <name><surname>Winandy</surname><given-names>M.</given-names></name>, <name><surname>van Montfoort</surname><given-names>A. P.</given-names></name>, <name><surname>Tarbashevich</surname><given-names>K.</given-names></name>, <name><surname>Raz</surname><given-names>E.</given-names></name>, <name><surname>Gerards</surname><given-names>M.</given-names></name>, <etal>et al</etal>
<article-title>Differences in strength and timing of the mtDNA bottleneck between zebrafish germline and non-germline cells</article-title>. <source><italic toggle="yes">Cell Reports</italic></source>
<volume>16</volume>(<issue>3</issue>), <fpage>622</fpage>&#x02013;<lpage>630</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1016/j.celrep.2016.06.023</pub-id>
<?supplied-pmid 27373161?><pub-id pub-id-type="pmid">27373161</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Tang</surname><given-names>Y.</given-names></name>, <name><surname>Schon</surname><given-names>E. A.</given-names></name>, <name><surname>Wilichowski</surname><given-names>E.</given-names></name>, <name><surname>Vazquez-Memije</surname><given-names>M. E.</given-names></name>, <name><surname>Davidson</surname><given-names>E.</given-names></name>, and <name><surname>King</surname><given-names>M. P</given-names></name>. <article-title>Rearrangements of human mitochondrial DNA (mtDNA): new insights into the regulation of mtDNA copy number and gene expression</article-title>. <source><italic toggle="yes">Molecular biology of the cell</italic></source>
<volume>11</volume>(<issue>4</issue>), <fpage>1471</fpage>&#x02013;<lpage>1485</lpage> (<year>2000</year>). <pub-id pub-id-type="doi">10.1091/mbc.11.4.1471</pub-id>
<?supplied-pmid 10749943?><pub-id pub-id-type="pmid">10749943</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Diaz</surname><given-names>F.</given-names></name>, <name><surname>Bayona-Bafaluy</surname><given-names>M. P.</given-names></name>, <name><surname>Rana</surname><given-names>M.</given-names></name>, <name><surname>Mora</surname><given-names>M.</given-names></name>, <name><surname>Hao</surname><given-names>H.</given-names></name>, and <name><surname>Moraes</surname><given-names>C. T</given-names></name>. <article-title>Human mitochondrial DNA with large deletions repopulates organelles faster than full-length genomes under relaxed copy number control</article-title>. <source><italic toggle="yes">Nucleic acids research</italic></source>
<volume>30</volume>(<issue>21</issue>), <fpage>4626</fpage>&#x02013;<lpage>4633</lpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1093/nar/gkf602</pub-id>
<?supplied-pmid 12409452?><pub-id pub-id-type="pmid">12409452</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Kowald</surname><given-names>A.</given-names></name> and <name><surname>Kirkwood</surname><given-names>T. B.</given-names></name>
<article-title>Transcription could be the key to the selection advantage of mitochondrial deletion mutants in aging</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source>
<volume>111</volume>(<issue>8</issue>), <fpage>2972</fpage>&#x02013;<lpage>2977</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1073/pnas.1314970111</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Burgstaller</surname><given-names>J. P.</given-names></name>, <name><surname>Johnston</surname><given-names>I. G.</given-names></name>, and <name><surname>Poulton</surname><given-names>J</given-names></name>. <article-title>Mitochondrial dna disease and developmental implications for reproductive strategies</article-title>. <source><italic toggle="yes">Molecular human reproduction</italic></source>
<volume>21</volume>(<issue>1</issue>), <fpage>11</fpage>&#x02013;<lpage>22</lpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1093/molehr/gau090</pub-id>
<?supplied-pmid 25425607?><pub-id pub-id-type="pmid">25425607</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>R&#x000f8;yrvik</surname><given-names>E.</given-names></name>, <name><surname>Burgstaller</surname><given-names>J. P.</given-names></name>, and <name><surname>Johnston</surname><given-names>I. G</given-names></name>. <article-title>mtDNA diversity in human populations highlights the merit of haplotype matching in gene therapies</article-title>. <source><italic toggle="yes">Molecular Human Reproduction</italic></source>
<volume>22</volume>(<issue>11</issue>), <fpage>809</fpage>&#x02013;<lpage>817</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1093/molehr/gaw062</pub-id>
<?supplied-pmid 27609757?><pub-id pub-id-type="pmid">27609757</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>Y.-G.</given-names></name>, <name><surname>Cha</surname><given-names>J.</given-names></name>, and <name><surname>Chandrasegaran</surname><given-names>S</given-names></name>. <article-title>Hybrid restriction enzymes: zinc finger fusions to Fok i cleavage domain</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source>
<volume>93</volume>(<issue>3</issue>), <fpage>1156</fpage>&#x02013;<lpage>1160</lpage> (<year>1996</year>). <pub-id pub-id-type="doi">10.1073/pnas.93.3.1156</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Urnov</surname><given-names>F. D.</given-names></name>, <name><surname>Miller</surname><given-names>J. C.</given-names></name>, <name><surname>Lee</surname><given-names>Y.-L.</given-names></name>, <name><surname>Beausejour</surname><given-names>C. M.</given-names></name>, <name><surname>Rock</surname><given-names>J. M.</given-names></name>, <name><surname>Augustus</surname><given-names>S.</given-names></name>, <name><surname>Jamieson</surname><given-names>A. C.</given-names></name>, <name><surname>Porteus</surname><given-names>M. H.</given-names></name>, <name><surname>Gregory</surname><given-names>P. D.</given-names></name>, and <name><surname>Holmes</surname><given-names>M. C</given-names></name>. <article-title>Highly efficient endogenous human gene correction using designed zinc-finger nucleases</article-title>. <source><italic toggle="yes">Nature</italic></source>
<volume>435</volume> (<issue>7042</issue>), <fpage>646</fpage>&#x02013;<lpage>651</lpage> (<year>2005</year>). <pub-id pub-id-type="doi">10.1038/nature03556</pub-id>
<?supplied-pmid 15806097?><pub-id pub-id-type="pmid">15806097</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Bibikova</surname><given-names>M.</given-names></name>, <name><surname>Golic</surname><given-names>M.</given-names></name>, <name><surname>Golic</surname><given-names>K. G.</given-names></name>, and <name><surname>Carroll</surname><given-names>D</given-names></name>. <article-title>Targeted chromosomal cleavage and mutagenesis in drosophila using zinc-finger nucleases</article-title>. <source><italic toggle="yes">Genetics</italic></source>
<volume>161</volume>(<issue>3</issue>), <fpage>1169</fpage>&#x02013;<lpage>1175</lpage> (<year>2002</year>). <?supplied-pmid 12136019?><pub-id pub-id-type="pmid">12136019</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Christian</surname><given-names>M.</given-names></name>, <name><surname>Cermak</surname><given-names>T.</given-names></name>, <name><surname>Doyle</surname><given-names>E. L.</given-names></name>, <name><surname>Schmidt</surname><given-names>C.</given-names></name>, <name><surname>Zhang</surname><given-names>F.</given-names></name>, <name><surname>Hummel</surname><given-names>A.</given-names></name>, <name><surname>Bogdanove</surname><given-names>A. J.</given-names></name>, and <name><surname>Voytas</surname><given-names>D. F</given-names></name>. <article-title>Targeting dna double-strand breaks with tal effector nucleases</article-title>. <source><italic toggle="yes">Genetics</italic></source>
<volume>186</volume>(<issue>2</issue>), <fpage>757</fpage>&#x02013;<lpage>761</lpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1534/genetics.110.120717</pub-id>
<?supplied-pmid 20660643?><pub-id pub-id-type="pmid">20660643</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>T.</given-names></name>, <name><surname>Huang</surname><given-names>S.</given-names></name>, <name><surname>Zhao</surname><given-names>X.</given-names></name>, <name><surname>Wright</surname><given-names>D. A.</given-names></name>, <name><surname>Carpenter</surname><given-names>S.</given-names></name>, <name><surname>Spalding</surname><given-names>M. H.</given-names></name>, <name><surname>Weeks</surname><given-names>D. P.</given-names></name>, and <name><surname>Yang</surname><given-names>B</given-names></name>. <article-title>Modularly assembled designer tal effector nucleases for targeted gene knockout and gene replacement in eukaryotes</article-title>. <source><italic toggle="yes">Nucleic acids research</italic></source>, <fpage>gkr188</fpage> (<year>2011</year>).</mixed-citation></ref><ref id="pcbi.1007023.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Miller</surname><given-names>J. C.</given-names></name>, <name><surname>Tan</surname><given-names>S.</given-names></name>, <name><surname>Qiao</surname><given-names>G.</given-names></name>, <name><surname>Barlow</surname><given-names>K. A.</given-names></name>, <name><surname>Wang</surname><given-names>J.</given-names></name>, <name><surname>Xia</surname><given-names>D. F.</given-names></name>, <name><surname>Meng</surname><given-names>X.</given-names></name>, <name><surname>Paschon</surname><given-names>D. E.</given-names></name>, <name><surname>Leung</surname><given-names>E.</given-names></name>, <name><surname>Hinkley</surname><given-names>S. J.</given-names></name>, <etal>et al</etal>
<article-title>A TALE nuclease architecture for efficient genome editing</article-title>. <source><italic toggle="yes">Nature biotechnology</italic></source>
<volume>29</volume>(<issue>2</issue>), <fpage>143</fpage>&#x02013;<lpage>148</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1038/nbt.1755</pub-id>
<?supplied-pmid 21179091?><pub-id pub-id-type="pmid">21179091</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref031"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Joung</surname><given-names>J. K.</given-names></name> and <name><surname>Sander</surname><given-names>J. D.</given-names></name>
<article-title>TALENs: a widely applicable technology for targeted genome editing</article-title>. <source><italic toggle="yes">Nature reviews Molecular cell biology</italic></source>
<volume>14</volume>(<issue>1</issue>), <fpage>49</fpage>&#x02013;<lpage>55</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1038/nrm3486</pub-id>
<?supplied-pmid 23169466?><pub-id pub-id-type="pmid">23169466</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref032"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Bacman</surname><given-names>S. R.</given-names></name>, <name><surname>Williams</surname><given-names>S. L.</given-names></name>, <name><surname>Pinto</surname><given-names>M.</given-names></name>, <name><surname>Peralta</surname><given-names>S.</given-names></name>, and <name><surname>Moraes</surname><given-names>C. T</given-names></name>. <article-title>Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs</article-title>. <source><italic toggle="yes">Nature Medicine</italic></source>
<volume>19</volume>(<issue>9</issue>), <fpage>1111</fpage>&#x02013;<lpage>1113</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1038/nm.3261</pub-id>
<?supplied-pmid 23913125?><pub-id pub-id-type="pmid">23913125</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref033"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Reddy</surname><given-names>P.</given-names></name>, <name><surname>Ocampo</surname><given-names>A.</given-names></name>, <name><surname>Suzuki</surname><given-names>K.</given-names></name>, <name><surname>Luo</surname><given-names>J.</given-names></name>, <name><surname>Bacman</surname><given-names>S. R.</given-names></name>, <name><surname>Williams</surname><given-names>S. L.</given-names></name>, <name><surname>Sugawara</surname><given-names>A.</given-names></name>, <name><surname>Okamura</surname><given-names>D.</given-names></name>, <name><surname>Tsunekawa</surname><given-names>Y.</given-names></name>, <name><surname>Wu</surname><given-names>J.</given-names></name>, <name><surname>Lam</surname><given-names>D.</given-names></name>, <name><surname>Xiong</surname><given-names>X.</given-names></name>, <name><surname>Montserrat</surname><given-names>N.</given-names></name>, <name><surname>Esteban</surname><given-names>C. R.</given-names></name>, <name><surname>Liu</surname><given-names>G.-H.</given-names></name>, <name><surname>Sancho-Martinez</surname><given-names>I.</given-names></name>, <name><surname>Manau</surname><given-names>D.</given-names></name>, <name><surname>Civico</surname><given-names>S.</given-names></name>, <name><surname>Cardellach</surname><given-names>F.</given-names></name>, <name><surname>del Mar O&#x02019;Callaghan</surname><given-names>M.</given-names></name>, <name><surname>Campistol</surname><given-names>J.</given-names></name>, <name><surname>Zhao</surname><given-names>H.</given-names></name>, <name><surname>Campistol</surname><given-names>J. M.</given-names></name>, <name><surname>Moraes</surname><given-names>C. T.</given-names></name>, and <name><surname>Belmonte</surname><given-names>J. C. I</given-names></name>. <article-title>Selective elimination of mitochondrial mutations in the germline by genome editing</article-title>. <source><italic toggle="yes">Cell</italic></source>
<volume>161</volume>(<issue>3</issue>), <fpage>459</fpage>&#x02013;<lpage>469</lpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2015.03.051</pub-id>
<?supplied-pmid 25910206?><pub-id pub-id-type="pmid">25910206</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref034"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Bacman</surname><given-names>S. R.</given-names></name>, <name><surname>Williams</surname><given-names>S. L.</given-names></name>, <name><surname>Pinto</surname><given-names>M.</given-names></name>, and <name><surname>Moraes</surname><given-names>C. T</given-names></name>. <article-title>The use of mitochondria-targeted endonucleases to manipulate mtDNA</article-title>. <source><italic toggle="yes">Methods in enzymology</italic></source>
<volume>547</volume>, <fpage>373</fpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1016/B978-0-12-801415-8.00018-7</pub-id>
<?supplied-pmid 25416366?><pub-id pub-id-type="pmid">25416366</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref035"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Gammage</surname><given-names>P. A.</given-names></name>, <name><surname>Van Haute</surname><given-names>L.</given-names></name>, and <name><surname>Minczuk</surname><given-names>M</given-names></name>. <article-title>Engineered mtZFNs for manipulation of human mitochondrial DNA heteroplasmy</article-title>. <source><italic toggle="yes">Mitochondrial DNA: Methods and Protocols</italic></source>, <fpage>145</fpage>&#x02013;<lpage>162</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1007/978-1-4939-3040-1_11</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref036"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Gammage</surname><given-names>P. A.</given-names></name>, <name><surname>Gaude</surname><given-names>E.</given-names></name>, <name><surname>Van Haute</surname><given-names>L.</given-names></name>, <name><surname>Rebelo-Guiomar</surname><given-names>P.</given-names></name>, <name><surname>Jackson</surname><given-names>C. B.</given-names></name>, <name><surname>Rorbach</surname><given-names>J.</given-names></name>, <name><surname>Pekalski</surname><given-names>M. L.</given-names></name>, <name><surname>Robinson</surname><given-names>A. J.</given-names></name>, <name><surname>Charpentier</surname><given-names>M.</given-names></name>, <name><surname>Concordet</surname><given-names>J.-P.</given-names></name>, <etal>et al</etal>
<article-title>Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, <fpage>7804</fpage>&#x02013;<lpage>7816</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1093/nar/gkw676</pub-id>
<?supplied-pmid 27466392?><pub-id pub-id-type="pmid">27466392</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref037"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Hashimoto</surname><given-names>M.</given-names></name>, <name><surname>Bacman</surname><given-names>S. R.</given-names></name>, <name><surname>Peralta</surname><given-names>S.</given-names></name>, <name><surname>Falk</surname><given-names>M. J.</given-names></name>, <name><surname>Chomyn</surname><given-names>A.</given-names></name>, <name><surname>Chan</surname><given-names>D. C.</given-names></name>, <name><surname>Williams</surname><given-names>L. S.</given-names></name>, and <name><surname>Moraes</surname><given-names>C. T</given-names></name>. <article-title>Mitotalen: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases</article-title>. <source><italic toggle="yes">Molecular Therapy</italic></source> (<year>2015</year>). <pub-id pub-id-type="doi">10.1038/mt.2015.126</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref038"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Johnston</surname><given-names>I. G.</given-names></name> and <name><surname>Jones</surname><given-names>N. S.</given-names></name>
<article-title>Evolution of cell-to-cell variability in stochastic, controlled, heteroplasmic mtdna populations</article-title>. <source><italic toggle="yes">The American Journal of Human Genetics</italic></source>
<volume>99</volume>(<issue>5</issue>), <fpage>1150</fpage>&#x02013;<lpage>1162</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.09.016</pub-id>
<?supplied-pmid 27843124?><pub-id pub-id-type="pmid">27843124</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref039"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Gross</surname><given-names>N. J.</given-names></name>, <name><surname>Getz</surname><given-names>G. S.</given-names></name>, and <name><surname>Rabinowitz</surname><given-names>M</given-names></name>. <article-title>Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat</article-title>. <source><italic toggle="yes">Journal of Biological Chemistry</italic></source>
<volume>244</volume>(<issue>6</issue>), <fpage>1552</fpage>&#x02013;<lpage>1562</lpage> (<year>1969</year>). <?supplied-pmid 5773057?><pub-id pub-id-type="pmid">5773057</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref040"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Chinnery</surname><given-names>P. F.</given-names></name> and <name><surname>Samuels</surname><given-names>D. C.</given-names></name>
<article-title>Relaxed replication of mtDNA: a model with implications for the expression of disease</article-title>. <source><italic toggle="yes">The American Journal of Human Genetics</italic></source>
<volume>64</volume>(<issue>4</issue>), <fpage>1158</fpage>&#x02013;<lpage>1165</lpage> (<year>1999</year>). <pub-id pub-id-type="doi">10.1086/302311</pub-id>
<?supplied-pmid 10090901?><pub-id pub-id-type="pmid">10090901</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref041"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Capps</surname><given-names>G. J.</given-names></name>, <name><surname>Samuels</surname><given-names>D. C.</given-names></name>, and <name><surname>Chinnery</surname><given-names>P. F</given-names></name>. <article-title>A model of the nuclear control of mitochondrial DNA replication</article-title>. <source><italic toggle="yes">Journal of theoretical biology</italic></source>
<volume>221</volume>(<issue>4</issue>), <fpage>565</fpage>&#x02013;<lpage>583</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1006/jtbi.2003.3207</pub-id>
<?supplied-pmid 12713941?><pub-id pub-id-type="pmid">12713941</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Elson</surname><given-names>J.</given-names></name>, <name><surname>Samuels</surname><given-names>D.</given-names></name>, <name><surname>Turnbull</surname><given-names>D.</given-names></name>, and <name><surname>Chinnery</surname><given-names>P</given-names></name>. <article-title>Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age</article-title>. <source><italic toggle="yes">The American Journal of Human Genetics</italic></source>
<volume>68</volume>(<issue>3</issue>), <fpage>802</fpage>&#x02013;<lpage>806</lpage> (<year>2001</year>). <pub-id pub-id-type="doi">10.1086/318801</pub-id>
<?supplied-pmid 11179029?><pub-id pub-id-type="pmid">11179029</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref043"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Kowald</surname><given-names>A.</given-names></name> and <name><surname>Kirkwood</surname><given-names>T. B.</given-names></name>
<article-title>Mitochondrial mutations and aging: random drift is insufficient to explain the accumulation of mitochondrial deletion mutants in short-lived animals</article-title>. <source><italic toggle="yes">Aging cell</italic></source>
<volume>12</volume>(<issue>4</issue>), <fpage>728</fpage>&#x02013;<lpage>731</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1111/acel.12098</pub-id>
<?supplied-pmid 23742009?><pub-id pub-id-type="pmid">23742009</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref044"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Lill</surname><given-names>R.</given-names></name>, <name><surname>Hoffmann</surname><given-names>B.</given-names></name>, <name><surname>Molik</surname><given-names>S.</given-names></name>, <name><surname>Pierik</surname><given-names>A. J.</given-names></name>, <name><surname>Rietzschel</surname><given-names>N.</given-names></name>, <name><surname>Stehling</surname><given-names>O.</given-names></name>, <name><surname>Uzarska</surname><given-names>M. A.</given-names></name>, <name><surname>Webert</surname><given-names>H.</given-names></name>, <name><surname>Wilbrecht</surname><given-names>C.</given-names></name>, and <name><surname>M&#x000fc;hlenhoff</surname><given-names>U</given-names></name>. <article-title>The role of mitochondria in cellular iron&#x02013;sulfur protein biogenesis and iron metabolism</article-title>. <source><italic toggle="yes">Biochimica et Biophysica Acta (BBA)-Molecular Cell Research</italic></source>
<volume>1823</volume>(<issue>9</issue>), <fpage>1491</fpage>&#x02013;<lpage>1508</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.05.009</pub-id><pub-id pub-id-type="pmid">22609301</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref045"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>C.</given-names></name> and <name><surname>Youle</surname><given-names>R. J.</given-names></name>
<article-title>The role of mitochondria in apoptosis</article-title>. <source><italic toggle="yes">Annual review of genetics</italic></source>
<volume>43</volume>, <fpage>95</fpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1146/annurev-genet-102108-134850</pub-id>
<?supplied-pmid 19659442?><pub-id pub-id-type="pmid">19659442</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref046"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Rizzuto</surname><given-names>R.</given-names></name>, <name><surname>De Stefani</surname><given-names>D.</given-names></name>, <name><surname>Raffaello</surname><given-names>A.</given-names></name>, and <name><surname>Mammucari</surname><given-names>C</given-names></name>. <article-title>Mitochondria as sensors and regulators of calcium signalling</article-title>. <source><italic toggle="yes">Nature reviews Molecular cell biology</italic></source>
<volume>13</volume>(<issue>9</issue>), <fpage>566</fpage>&#x02013;<lpage>578</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1038/nrm3412</pub-id>
<?supplied-pmid 22850819?><pub-id pub-id-type="pmid">22850819</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref047"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Mor&#x000e1;n</surname><given-names>M.</given-names></name>, <name><surname>Moreno-Lastres</surname><given-names>D.</given-names></name>, <name><surname>Mar&#x000ed;n-Buera</surname><given-names>L.</given-names></name>, <name><surname>Arenas</surname><given-names>J.</given-names></name>, <name><surname>Mart&#x000ed;n</surname><given-names>M. A.</given-names></name>, and <name><surname>Ugalde</surname><given-names>C</given-names></name>. <article-title>Mitochondrial respiratory chain dysfunction: implications in neurodegeneration</article-title>. <source><italic toggle="yes">Free Radical Biology and Medicine</italic></source>
<volume>53</volume>(<issue>3</issue>), <fpage>595</fpage>&#x02013;<lpage>609</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.05.009</pub-id>
<?supplied-pmid 22595027?><pub-id pub-id-type="pmid">22595027</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref048"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Monternier</surname><given-names>P.-A.</given-names></name>, <name><surname>Marmillot</surname><given-names>V.</given-names></name>, <name><surname>Rouanet</surname><given-names>J.-L.</given-names></name>, and <name><surname>Roussel</surname><given-names>D</given-names></name>. <article-title>Mitochondrial phenotypic flexibility enhances energy savings during winter fast in king penguin chicks</article-title>. <source><italic toggle="yes">Journal of Experimental Biology</italic></source>
<volume>217</volume>(<issue>15</issue>), <fpage>2691</fpage>&#x02013;<lpage>2697</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1242/jeb.104505</pub-id>
<?supplied-pmid 24803465?><pub-id pub-id-type="pmid">24803465</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref049"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Salin</surname><given-names>K.</given-names></name>, <name><surname>Roussel</surname><given-names>D.</given-names></name>, <name><surname>Rey</surname><given-names>B.</given-names></name>, and <name><surname>Voituron</surname><given-names>Y.</given-names></name>
<article-title>David and Goliath: a mitochondrial coupling problem?</article-title>
<source><italic toggle="yes">Journal of Experimental Zoology Part A: Ecological Genetics and Physiology</italic></source>
<volume>317</volume>(<issue>5</issue>), <fpage>283</fpage>&#x02013;<lpage>293</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1002/jez.1722</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref050"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Brand</surname><given-names>M. D.</given-names></name>, <name><surname>Harper</surname><given-names>M.-E.</given-names></name>, and <name><surname>Taylor</surname><given-names>H. C</given-names></name>. <article-title>Control of the effective P/O ratio of oxidative phosphorylation in liver mitochondria and hepatocytes</article-title>. <source><italic toggle="yes">Biochemical Journal</italic></source>
<volume>291</volume>(<issue>3</issue>), <fpage>739</fpage>&#x02013;<lpage>748</lpage> (<year>1993</year>). <pub-id pub-id-type="doi">10.1042/bj2910739</pub-id>
<?supplied-pmid 8489502?><pub-id pub-id-type="pmid">8489502</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref051"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Yadava</surname><given-names>N.</given-names></name> and <name><surname>Nicholls</surname><given-names>D. G.</given-names></name>
<article-title>Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex i with rotenone</article-title>. <source><italic toggle="yes">The Journal of neuroscience</italic></source>
<volume>27</volume>(<issue>27</issue>), <fpage>7310</fpage>&#x02013;<lpage>7317</lpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0212-07.2007</pub-id>
<?supplied-pmid 17611283?><pub-id pub-id-type="pmid">17611283</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref052"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Hill</surname><given-names>B. G.</given-names></name>, <name><surname>Dranka</surname><given-names>B. P.</given-names></name>, <name><surname>Zou</surname><given-names>L.</given-names></name>, <name><surname>Chatham</surname><given-names>J. C.</given-names></name>, and <name><surname>Darley-Usmar</surname><given-names>V. M</given-names></name>. <article-title>Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal</article-title>. <source><italic toggle="yes">Biochemical Journal</italic></source>
<volume>424</volume>(<issue>1</issue>), <fpage>99</fpage>&#x02013;<lpage>107</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1042/BJ20090934</pub-id>
<?supplied-pmid 19740075?><pub-id pub-id-type="pmid">19740075</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref053"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Pfeiffer</surname><given-names>T.</given-names></name>, <name><surname>Schuster</surname><given-names>S.</given-names></name>, and <name><surname>Bonhoeffer</surname><given-names>S</given-names></name>. <article-title>Cooperation and competition in the evolution of atp-producing pathways</article-title>. <source><italic toggle="yes">Science</italic></source>
<volume>292</volume> (<issue>5516</issue>), <fpage>504</fpage>&#x02013;<lpage>507</lpage> (<year>2001</year>). <pub-id pub-id-type="doi">10.1126/science.1058079</pub-id>
<?supplied-pmid 11283355?><pub-id pub-id-type="pmid">11283355</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref054"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Angulo-Brown</surname><given-names>F.</given-names></name>, <name><surname>Santill&#x000e1;n</surname><given-names>M.</given-names></name>, and <name><surname>Calleja-Quevedo</surname><given-names>E</given-names></name>. <article-title>Thermodynamic optimality in some biochemical reactions</article-title>. <source><italic toggle="yes">Il Nuovo Cimento D</italic></source>
<volume>17</volume>(<issue>1</issue>), <fpage>87</fpage>&#x02013;<lpage>90</lpage> (<year>1995</year>). <pub-id pub-id-type="doi">10.1007/BF02451604</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref055"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Waddell</surname><given-names>T. G.</given-names></name>, <name><surname>Repovic</surname><given-names>P.</given-names></name>, <name><surname>Mel&#x000e9;ndez-Hevia</surname><given-names>E.</given-names></name>, <name><surname>Heinrich</surname><given-names>R.</given-names></name>, and <name><surname>Montero</surname><given-names>F</given-names></name>. <article-title>Optimization of glycolysis: new discussions</article-title>. <source><italic toggle="yes">Biochemistry and Molecular Biology Education</italic></source>
<volume>27</volume>(<issue>1</issue>), <fpage>12</fpage>&#x02013;<lpage>13</lpage> (<year>1999</year>).</mixed-citation></ref><ref id="pcbi.1007023.ref056"><label>56</label><mixed-citation publication-type="journal">
<name><surname>van Dijken</surname><given-names>J. P.</given-names></name>, <name><surname>Weusthuis</surname><given-names>R. A.</given-names></name>, and <name><surname>Pronk</surname><given-names>J. T</given-names></name>. <article-title>Kinetics of growth and sugar consumption in yeasts</article-title>. <source><italic toggle="yes">Antonie van leeuwenhoek</italic></source>
<volume>63</volume>(<issue>3-4</issue>), <fpage>343</fpage>&#x02013;<lpage>352</lpage> (<year>1993</year>). <pub-id pub-id-type="doi">10.1007/BF00871229</pub-id>
<?supplied-pmid 8279829?><pub-id pub-id-type="pmid">8279829</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref057"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Sriskanthadevan</surname><given-names>S.</given-names></name>, <name><surname>Jeyaraju</surname><given-names>D. V.</given-names></name>, <name><surname>Chung</surname><given-names>T. E.</given-names></name>, <name><surname>Prabha</surname><given-names>S.</given-names></name>, <name><surname>Xu</surname><given-names>W.</given-names></name>, <name><surname>Skrtic</surname><given-names>M.</given-names></name>, <name><surname>Jhas</surname><given-names>B.</given-names></name>, <name><surname>Hurren</surname><given-names>R.</given-names></name>, <name><surname>Gronda</surname><given-names>M.</given-names></name>, <name><surname>Wang</surname><given-names>X.</given-names></name>, <etal>et al</etal>
<article-title>Aml cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress</article-title>. <source><italic toggle="yes">Blood</italic></source>
<volume>125</volume>(<issue>13</issue>), <fpage>2120</fpage>&#x02013;<lpage>2130</lpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1182/blood-2014-08-594408</pub-id>
<?supplied-pmid 25631767?><pub-id pub-id-type="pmid">25631767</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref058"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Pfleger</surname><given-names>J.</given-names></name>, <name><surname>He</surname><given-names>M.</given-names></name>, and <name><surname>Abdellatif</surname><given-names>M</given-names></name>. <article-title>Mitochondrial complex ii is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival</article-title>. <source><italic toggle="yes">Cell death &#x00026; disease</italic></source>
<volume>6</volume>(<issue>7</issue>), <fpage>e1835</fpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1038/cddis.2015.202</pub-id><pub-id pub-id-type="pmid">26225774</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref059"><label>59</label><mixed-citation publication-type="journal">
<name><surname>Sharpley</surname><given-names>M. S.</given-names></name>, <name><surname>Marciniak</surname><given-names>C.</given-names></name>, <name><surname>Eckel-Mahan</surname><given-names>K.</given-names></name>, <name><surname>McManus</surname><given-names>M.</given-names></name>, <name><surname>Crimi</surname><given-names>M.</given-names></name>, <name><surname>Waymire</surname><given-names>K.</given-names></name>, <name><surname>Lin</surname><given-names>C. S.</given-names></name>, <name><surname>Masubuchi</surname><given-names>S.</given-names></name>, <name><surname>Friend</surname><given-names>N.</given-names></name>, <name><surname>Koike</surname><given-names>M.</given-names></name>, <etal>et al</etal>
<article-title>Heteroplasmy of mouse mtDNA is genetically unstable and results in altered behavior and cognition</article-title>. <source><italic toggle="yes">Cell</italic></source>
<volume>151</volume>(<issue>2</issue>), <fpage>333</fpage>&#x02013;<lpage>343</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2012.09.004</pub-id>
<?supplied-pmid 23063123?><pub-id pub-id-type="pmid">23063123</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref060"><label>60</label><mixed-citation publication-type="journal">
<name><surname>Minczuk</surname><given-names>M.</given-names></name>, <name><surname>Papworth</surname><given-names>M. A.</given-names></name>, <name><surname>Kolasinska</surname><given-names>P.</given-names></name>, <name><surname>Murphy</surname><given-names>M. P.</given-names></name>, and <name><surname>Klug</surname><given-names>A</given-names></name>. <article-title>Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source>
<volume>103</volume>(<issue>52</issue>), <fpage>19689</fpage>&#x02013;<lpage>19694</lpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1073/pnas.0609502103</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref061"><label>61</label><mixed-citation publication-type="journal">
<name><surname>Minczuk</surname><given-names>M.</given-names></name>, <name><surname>Papworth</surname><given-names>M. A.</given-names></name>, <name><surname>Miller</surname><given-names>J. C.</given-names></name>, <name><surname>Murphy</surname><given-names>M. P.</given-names></name>, and <name><surname>Klug</surname><given-names>A</given-names></name>. <article-title>Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA</article-title>. <source><italic toggle="yes">Nucleic acids research</italic></source>
<volume>36</volume>(<issue>12</issue>), <fpage>3926</fpage>&#x02013;<lpage>3938</lpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1093/nar/gkn313</pub-id>
<?supplied-pmid 18511461?><pub-id pub-id-type="pmid">18511461</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref062"><label>62</label><mixed-citation publication-type="journal">
<name><surname>Gammage</surname><given-names>P. A.</given-names></name>, <name><surname>Rorbach</surname><given-names>J.</given-names></name>, <name><surname>Vincent</surname><given-names>A. I.</given-names></name>, <name><surname>Rebar</surname><given-names>E. J.</given-names></name>, and <name><surname>Minczuk</surname><given-names>M</given-names></name>. <article-title>Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations</article-title>. <source><italic toggle="yes">EMBO molecular medicine</italic></source>
<volume>6</volume>(<issue>4</issue>), <fpage>458</fpage>&#x02013;<lpage>466</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1002/emmm.201303672</pub-id>
<?supplied-pmid 24567072?><pub-id pub-id-type="pmid">24567072</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref063"><label>63</label><mixed-citation publication-type="journal">
<name><surname>Cree</surname><given-names>L. M.</given-names></name>, <name><surname>Samuels</surname><given-names>D. C.</given-names></name>, <name><surname>de Sousa Lopes</surname><given-names>S. C.</given-names></name>, <name><surname>Rajasimha</surname><given-names>H. K.</given-names></name>, <name><surname>Wonnapinij</surname><given-names>P.</given-names></name>, <name><surname>Mann</surname><given-names>J. R.</given-names></name>, <name><surname>Dahl</surname><given-names>H.-H. M.</given-names></name>, and <name><surname>Chinnery</surname><given-names>P. F.</given-names></name>
<article-title>A reduction of mitochondrial dna molecules during embryogenesis explains the rapid segregation of genotypes</article-title>. <source><italic toggle="yes">Nature genetics</italic></source>
<volume>40</volume>(<issue>2</issue>), <fpage>249</fpage>&#x02013;<lpage>254</lpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1038/ng.2007.63</pub-id>
<?supplied-pmid 18223651?><pub-id pub-id-type="pmid">18223651</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref064"><label>64</label><mixed-citation publication-type="journal">
<name><surname>Johnston</surname><given-names>I. G.</given-names></name>, <name><surname>Burgstaller</surname><given-names>J. P.</given-names></name>, <name><surname>Havlicek</surname><given-names>V.</given-names></name>, <name><surname>Kolbe</surname><given-names>T.</given-names></name>, <name><surname>R&#x000fc;licke</surname><given-names>T.</given-names></name>, <name><surname>Brem</surname><given-names>G.</given-names></name>, <name><surname>Poulton</surname><given-names>J.</given-names></name>, and <name><surname>Jones</surname><given-names>N. S</given-names></name>. <article-title>Stochastic modelling, bayesian inference, and new in vivo measurements elucidate the debated mtDNA bottleneck mechanism</article-title>. <source><italic toggle="yes">eLife</italic></source>
<volume>4</volume>, <fpage>e07464</fpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.7554/eLife.07464</pub-id>
<?supplied-pmid 26035426?><pub-id pub-id-type="pmid">26035426</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref065"><label>65</label><mixed-citation publication-type="journal">
<name><surname>Freyer</surname><given-names>C.</given-names></name>, <name><surname>Cree</surname><given-names>L. M.</given-names></name>, <name><surname>Mourier</surname><given-names>A.</given-names></name>, <name><surname>Stewart</surname><given-names>J. B.</given-names></name>, <name><surname>Koolmeister</surname><given-names>C.</given-names></name>, <name><surname>Milenkovic</surname><given-names>D.</given-names></name>, <name><surname>Wai</surname><given-names>T.</given-names></name>, <name><surname>Floros</surname><given-names>V. I.</given-names></name>, <name><surname>Hagstr&#x000f6;m</surname><given-names>E.</given-names></name>, <name><surname>Chatzidaki</surname><given-names>E. E.</given-names></name>, <etal>et al</etal>
<article-title>Variation in germline mtdna heteroplasmy is determined prenatally but modified during subsequent transmission</article-title>. <source><italic toggle="yes">Nature genetics</italic></source>
<volume>44</volume>(<issue>11</issue>), <fpage>1282</fpage>&#x02013;<lpage>1285</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1038/ng.2427</pub-id>
<?supplied-pmid 23042113?><pub-id pub-id-type="pmid">23042113</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref066"><label>66</label><mixed-citation publication-type="journal">
<name><surname>Stewart</surname><given-names>J. B.</given-names></name> and <name><surname>Chinnery</surname><given-names>P. F.</given-names></name>
<article-title>The dynamics of mitochondrial dna heteroplasmy: implications for human health and disease</article-title>. <source><italic toggle="yes">Nature Reviews Genetics</italic></source>
<volume>16</volume>(<issue>9</issue>), <fpage>530</fpage>&#x02013;<lpage>542</lpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1038/nrg3966</pub-id>
<?supplied-pmid 26281784?><pub-id pub-id-type="pmid">26281784</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref067"><label>67</label><mixed-citation publication-type="journal">
<name><surname>Kaufmann</surname><given-names>P.</given-names></name>, <name><surname>Shanske</surname><given-names>S.</given-names></name>, <name><surname>Hirano</surname><given-names>M.</given-names></name>, <name><surname>DiMauro</surname><given-names>S.</given-names></name>, <name><surname>King</surname><given-names>M. P.</given-names></name>, <name><surname>Koga</surname><given-names>Y.</given-names></name>, and <name><surname>Schon</surname><given-names>E. A</given-names></name>. <article-title>Mitochondrial DNA and RNA processing in melas</article-title>. <source><italic toggle="yes">Annals of neurology</italic></source>
<volume>40</volume>(<issue>2</issue>), <fpage>172</fpage>&#x02013;<lpage>180</lpage> (<year>1996</year>). <pub-id pub-id-type="doi">10.1002/ana.410400208</pub-id>
<?supplied-pmid 8773598?><pub-id pub-id-type="pmid">8773598</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref068"><label>68</label><mixed-citation publication-type="journal">
<name><surname>Shoubridge</surname><given-names>E. A.</given-names></name>, <name><surname>Karpati</surname><given-names>G.</given-names></name>, and <name><surname>Hastings</surname><given-names>K. E</given-names></name>. <article-title>Deletion mutants are functionally dominant over wild-type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial disease</article-title>. <source><italic toggle="yes">Cell</italic></source>
<volume>62</volume>(<issue>1</issue>), <fpage>43</fpage>&#x02013;<lpage>49</lpage> (<year>1990</year>). <pub-id pub-id-type="doi">10.1016/0092-8674(90)90238-A</pub-id>
<?supplied-pmid 2163769?><pub-id pub-id-type="pmid">2163769</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref069"><label>69</label><mixed-citation publication-type="journal">
<name><surname>Moraes</surname><given-names>C. T.</given-names></name>, <name><surname>Ricci</surname><given-names>E.</given-names></name>, <name><surname>Petruzzella</surname><given-names>V.</given-names></name>, <name><surname>Shanske</surname><given-names>S.</given-names></name>, <name><surname>DiMauro</surname><given-names>S.</given-names></name>, <name><surname>Schon</surname><given-names>E. A.</given-names></name>, and <name><surname>Bonilla</surname><given-names>E</given-names></name>. <article-title>Molecular analysis of the muscle pathology associated with mitochondrial DNA deletions</article-title>. <source><italic toggle="yes">Nature genetics</italic></source>
<volume>1</volume>(<issue>5</issue>), <fpage>359</fpage>&#x02013;<lpage>367</lpage> (<year>1992</year>). <pub-id pub-id-type="doi">10.1038/ng0892-359</pub-id>
<?supplied-pmid 1284549?><pub-id pub-id-type="pmid">1284549</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref070"><label>70</label><mixed-citation publication-type="journal">
<name><surname>Tokunaga</surname><given-names>M.</given-names></name>, <name><surname>Mita</surname><given-names>S.</given-names></name>, <name><surname>Murakami</surname><given-names>T.</given-names></name>, <name><surname>Kumamoto</surname><given-names>T.</given-names></name>, <name><surname>Uchino</surname><given-names>M.</given-names></name>, <name><surname>Nonaka</surname><given-names>I.</given-names></name>, and <name><surname>Ando</surname><given-names>M</given-names></name>. <article-title>Single muscle fiber analysis of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (melas)</article-title>. <source><italic toggle="yes">Annals of neurology</italic></source>
<volume>35</volume>(<issue>4</issue>), <fpage>413</fpage>&#x02013;<lpage>419</lpage> (<year>1994</year>). <pub-id pub-id-type="doi">10.1002/ana.410350407</pub-id>
<?supplied-pmid 8154867?><pub-id pub-id-type="pmid">8154867</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref071"><label>71</label><mixed-citation publication-type="journal">
<name><surname>Nicholas</surname><given-names>A.</given-names></name>, <name><surname>Kraytsberg</surname><given-names>Y.</given-names></name>, <name><surname>Guo</surname><given-names>X.</given-names></name>, and <name><surname>Khrapko</surname><given-names>K</given-names></name>. <article-title>On the timing and the extent of clonal expansion of mtDNA deletions: evidence from single-molecule pcr</article-title>. <source><italic toggle="yes">Experimental neurology</italic></source>
<volume>218</volume>(<issue>2</issue>), <fpage>316</fpage>&#x02013;<lpage>319</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1016/j.expneurol.2009.04.029</pub-id>
<?supplied-pmid 19426731?><pub-id pub-id-type="pmid">19426731</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref072"><label>72</label><mixed-citation publication-type="journal">
<name><surname>Schwarze</surname><given-names>S. R.</given-names></name>, <name><surname>Lee</surname><given-names>C. M.</given-names></name>, <name><surname>Chung</surname><given-names>S. S.</given-names></name>, <name><surname>Roecker</surname><given-names>E. B.</given-names></name>, <name><surname>Weindruch</surname><given-names>R.</given-names></name>, and <name><surname>Aiken</surname><given-names>J. M</given-names></name>. <article-title>High levels of mitochondrial DNA deletions in skeletal muscle of old rhesus monkeys</article-title>. <source><italic toggle="yes">Mechanisms of ageing and development</italic></source>
<volume>83</volume>(<issue>2</issue>), <fpage>91</fpage>&#x02013;<lpage>101</lpage> (<year>1995</year>). <pub-id pub-id-type="doi">10.1016/0047-6374(95)01611-3</pub-id>
<?supplied-pmid 8569289?><pub-id pub-id-type="pmid">8569289</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref073"><label>73</label><mixed-citation publication-type="journal">
<name><surname>Reznik</surname><given-names>E.</given-names></name>, <name><surname>Miller</surname><given-names>M. L.</given-names></name>, <name><surname>&#x0015e;enbabao&#x0011f;lu</surname><given-names>Y.</given-names></name>, <name><surname>Riaz</surname><given-names>N.</given-names></name>, <name><surname>Sarungbam</surname><given-names>J.</given-names></name>, <name><surname>Tickoo</surname><given-names>S. K.</given-names></name>, <name><surname>Al-Ahmadie</surname><given-names>H. A.</given-names></name>, <name><surname>Lee</surname><given-names>W.</given-names></name>, <name><surname>Seshan</surname><given-names>V. E.</given-names></name>, <name><surname>Hakimi</surname><given-names>A. A.</given-names></name>, <etal>et al</etal>
<article-title>Mitochondrial DNA copy number variation across human cancers</article-title>. <source><italic toggle="yes">eLife</italic></source>
<volume>5</volume>, <fpage>e10769</fpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.7554/eLife.10769</pub-id>
<?supplied-pmid 26901439?><pub-id pub-id-type="pmid">26901439</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref074"><label>74</label><mixed-citation publication-type="journal">
<name><surname>Majamaa-Voltti</surname><given-names>K.</given-names></name>, <name><surname>Peuhkurinen</surname><given-names>K.</given-names></name>, <name><surname>Kortelainen</surname><given-names>M.-L.</given-names></name>, <name><surname>Hassinen</surname><given-names>I. E.</given-names></name>, and <name><surname>Majamaa</surname><given-names>K</given-names></name>. <article-title>Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A&#x0003e;G</article-title>. <source><italic toggle="yes">BMC cardiovascular disorders</italic></source>
<volume>2</volume>(<issue>1</issue>), <fpage>12</fpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1186/1471-2261-2-12</pub-id>
<?supplied-pmid 12150714?><pub-id pub-id-type="pmid">12150714</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref075"><label>75</label><mixed-citation publication-type="journal">
<name><surname>Ciafaloni</surname><given-names>E.</given-names></name>, <name><surname>Ricci</surname><given-names>E.</given-names></name>, <name><surname>Servidei</surname><given-names>S.</given-names></name>, <name><surname>Shanske</surname><given-names>S.</given-names></name>, <name><surname>Silvestri</surname><given-names>G.</given-names></name>, <name><surname>Manfredi</surname><given-names>G.</given-names></name>, <name><surname>Schon</surname><given-names>E.</given-names></name>, and <name><surname>DiMauro</surname><given-names>S</given-names></name>. <article-title>Widespread tissue distribution of a trnaleu (uur) mutation in the mitochondrial DNA of a patient with melas syndrome</article-title>. <source><italic toggle="yes">Neurology</italic></source>
<volume>41</volume>(<issue>10</issue>), <fpage>1663</fpage>&#x02013;<lpage>1663</lpage> (<year>1991</year>). <pub-id pub-id-type="doi">10.1212/wnl.41.10.1663</pub-id>
<?supplied-pmid 1922812?><pub-id pub-id-type="pmid">1922812</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref076"><label>76</label><mixed-citation publication-type="journal">
<name><surname>Anan</surname><given-names>R.</given-names></name>, <name><surname>Nakagawa</surname><given-names>M.</given-names></name>, <name><surname>Miyata</surname><given-names>M.</given-names></name>, <name><surname>Higuchi</surname><given-names>I.</given-names></name>, <name><surname>Nakao</surname><given-names>S.</given-names></name>, <name><surname>Suehara</surname><given-names>M.</given-names></name>, <name><surname>Osame</surname><given-names>M.</given-names></name>, and <name><surname>Tanaka</surname><given-names>H</given-names></name>. <article-title>Cardiac involvement in mitochondrial diseases a study on 17 patients with documented mitochondrial DNA defects</article-title>. <source><italic toggle="yes">Circulation</italic></source>
<volume>91</volume>(<issue>4</issue>), <fpage>955</fpage>&#x02013;<lpage>961</lpage> (<year>1995</year>). <pub-id pub-id-type="doi">10.1161/01.CIR.91.4.955</pub-id>
<?supplied-pmid 7850981?><pub-id pub-id-type="pmid">7850981</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref077"><label>77</label><mixed-citation publication-type="journal">
<name><surname>Jeppesen</surname><given-names>T. D.</given-names></name>, <name><surname>Schwartz</surname><given-names>M.</given-names></name>, <name><surname>Olsen</surname><given-names>D. B.</given-names></name>, and <name><surname>Vissing</surname><given-names>J</given-names></name>. <article-title>Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy</article-title>. <source><italic toggle="yes">Annals of Neurology</italic></source>
<volume>54</volume>(<issue>1</issue>), <fpage>86</fpage>&#x02013;<lpage>92</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1002/ana.10594</pub-id>
<?supplied-pmid 12838523?><pub-id pub-id-type="pmid">12838523</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref078"><label>78</label><mixed-citation publication-type="journal">
<name><surname>Stein</surname><given-names>L. R.</given-names></name> and <name><surname>Imai</surname><given-names>S.-i.</given-names></name>
<article-title>The dynamic regulation of nad metabolism in mitochondria</article-title>. <source><italic toggle="yes">Trends in Endocrinology &#x00026; Metabolism</italic></source>
<volume>23</volume>(<issue>9</issue>), <fpage>420</fpage>&#x02013;<lpage>428</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1016/j.tem.2012.06.005</pub-id><pub-id pub-id-type="pmid">22819213</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref079"><label>79</label><mixed-citation publication-type="journal">
<name><surname>Alano</surname><given-names>C. C.</given-names></name>, <name><surname>Ying</surname><given-names>W.</given-names></name>, and <name><surname>Swanson</surname><given-names>R. A</given-names></name>. <article-title>Poly (adp-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition</article-title>. <source><italic toggle="yes">Journal of Biological Chemistry</italic></source>
<volume>279</volume>(<issue>18</issue>), <fpage>18895</fpage>&#x02013;<lpage>18902</lpage> (<year>2004</year>). <pub-id pub-id-type="doi">10.1074/jbc.M313329200</pub-id>
<?supplied-pmid 14960594?><pub-id pub-id-type="pmid">14960594</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref080"><label>80</label><mixed-citation publication-type="journal">
<name><surname>Bai</surname><given-names>P.</given-names></name>, <name><surname>Cant&#x000f3;</surname><given-names>C.</given-names></name>, <name><surname>Oudart</surname><given-names>H.</given-names></name>, <name><surname>Bruny&#x000e1;nszki</surname><given-names>A.</given-names></name>, <name><surname>Cen</surname><given-names>Y.</given-names></name>, <name><surname>Thomas</surname><given-names>C.</given-names></name>, <name><surname>Yamamoto</surname><given-names>H.</given-names></name>, <name><surname>Huber</surname><given-names>A.</given-names></name>, <name><surname>Kiss</surname><given-names>B.</given-names></name>, <name><surname>Houtkooper</surname><given-names>R. H.</given-names></name>, <etal>et al</etal>
<article-title>PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation</article-title>. <source><italic toggle="yes">Cell Metabolism</italic></source>
<volume>13</volume>(<issue>4</issue>), <fpage>461</fpage>&#x02013;<lpage>468</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1016/j.cmet.2011.03.004</pub-id>
<?supplied-pmid 21459330?><pub-id pub-id-type="pmid">21459330</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref081"><label>81</label><mixed-citation publication-type="journal">
<name><surname>Pittelli</surname><given-names>M.</given-names></name>, <name><surname>Felici</surname><given-names>R.</given-names></name>, <name><surname>Pitozzi</surname><given-names>V.</given-names></name>, <name><surname>Giovannelli</surname><given-names>L.</given-names></name>, <name><surname>Bigagli</surname><given-names>E.</given-names></name>, <name><surname>Cialdai</surname><given-names>F.</given-names></name>, <name><surname>Romano</surname><given-names>G.</given-names></name>, <name><surname>Moroni</surname><given-names>F.</given-names></name>, and <name><surname>Chiarugi</surname><given-names>A</given-names></name>. <article-title>Pharmacological effects of exogenous nad on mitochondrial bioenergetics, DNA repair, and apoptosis</article-title>. <source><italic toggle="yes">Molecular pharmacology</italic></source>
<volume>80</volume>(<issue>6</issue>), <fpage>1136</fpage>&#x02013;<lpage>1146</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1124/mol.111.073916</pub-id>
<?supplied-pmid 21917911?><pub-id pub-id-type="pmid">21917911</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref082"><label>82</label><mixed-citation publication-type="journal">
<name><surname>Korzeniewski</surname><given-names>B.</given-names></name>, <name><surname>Harper</surname><given-names>M.-E.</given-names></name>, and <name><surname>Brand</surname><given-names>M. D</given-names></name>. <article-title>Proportional activation coefficients during stimulation of oxidative phosphorylation by lactate and pyruvate or by vasopressin</article-title>. <source><italic toggle="yes">Biochimica et Biophysica Acta (BBA)-Bioenergetics</italic></source>
<volume>1229</volume>(<issue>3</issue>), <fpage>315</fpage>&#x02013;<lpage>322</lpage> (<year>1995</year>). <pub-id pub-id-type="doi">10.1016/0005-2728(95)00008-7</pub-id><pub-id pub-id-type="pmid">7748883</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref083"><label>83</label><mixed-citation publication-type="journal">
<name><surname>Nobes</surname><given-names>C.</given-names></name>, <name><surname>Hay</surname><given-names>W.</given-names></name>, and <name><surname>Brand</surname><given-names>M</given-names></name>. <article-title>The mechanism of stimulation of respiration by fatty acids in isolated hepatocytes</article-title>. <source><italic toggle="yes">Journal of Biological Chemistry</italic></source>
<volume>265</volume>(<issue>22</issue>), <fpage>12910</fpage>&#x02013;<lpage>12915</lpage> (<year>1990</year>). <?supplied-pmid 2376580?><pub-id pub-id-type="pmid">2376580</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref084"><label>84</label><mixed-citation publication-type="journal">
<name><surname>Affourtit</surname><given-names>C.</given-names></name> and <name><surname>Brand</surname><given-names>M. D.</given-names></name>
<article-title>Uncoupling protein-2 contributes significantly to high mitochondrial proton leak in INS-1E insulinoma cells and attenuates glucose-stimulated insulin secretion</article-title>. <source><italic toggle="yes">Biochemical Journal</italic></source>
<volume>409</volume>(<issue>1</issue>), <fpage>199</fpage>&#x02013;<lpage>204</lpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1042/BJ20070954</pub-id>
<?supplied-pmid 17824844?><pub-id pub-id-type="pmid">17824844</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref085"><label>85</label><mixed-citation publication-type="journal">
<name><surname>Michikawa</surname><given-names>Y.</given-names></name>, <name><surname>Mazzucchelli</surname><given-names>F.</given-names></name>, <name><surname>Bresolin</surname><given-names>N.</given-names></name>, <name><surname>Scarlato</surname><given-names>G.</given-names></name>, and <name><surname>Attardi</surname><given-names>G</given-names></name>. <article-title>Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication</article-title>. <source><italic toggle="yes">Science</italic></source>
<volume>286</volume> (<issue>5440</issue>), <fpage>774</fpage>&#x02013;<lpage>779</lpage> (<year>1999</year>). <pub-id pub-id-type="doi">10.1126/science.286.5440.774</pub-id>
<?supplied-pmid 10531063?><pub-id pub-id-type="pmid">10531063</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref086"><label>86</label><mixed-citation publication-type="journal">
<name><surname>Wallace</surname><given-names>D. C.</given-names></name>
<article-title>Mitochondrial genetics: a paradigm for aging and degenerative diseases?</article-title>
<source><italic toggle="yes">Science</italic></source>
<volume>256</volume> (<issue>5057</issue>), <fpage>628</fpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1533953</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref087"><label>87</label><mixed-citation publication-type="journal">
<name><surname>Kowald</surname><given-names>A.</given-names></name> and <name><surname>Klipp</surname><given-names>E.</given-names></name>
<article-title>Mathematical models of mitochondrial aging and dynamics</article-title>. <source><italic toggle="yes">Prog Mol Biol Transl Sci</italic></source>
<volume>127</volume>, <fpage>63</fpage>&#x02013;<lpage>92</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1016/B978-0-12-394625-6.00003-9</pub-id>
<?supplied-pmid 25149214?><pub-id pub-id-type="pmid">25149214</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref088"><label>88</label><mixed-citation publication-type="journal">
<name><surname>Yoneda</surname><given-names>M.</given-names></name>, <name><surname>Chomyn</surname><given-names>A.</given-names></name>, <name><surname>Martinuzzi</surname><given-names>A.</given-names></name>, <name><surname>Hurko</surname><given-names>O.</given-names></name>, and <name><surname>Attardi</surname><given-names>G</given-names></name>. <article-title>Marked replicative advantage of human mtDNA carrying a point mutation that causes the melas encephalomyopathy</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source>
<volume>89</volume>(<issue>23</issue>), <fpage>11164</fpage>&#x02013;<lpage>11168</lpage> (<year>1992</year>). <pub-id pub-id-type="doi">10.1073/pnas.89.23.11164</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref089"><label>89</label><mixed-citation publication-type="journal">
<name><surname>Kowald</surname><given-names>A.</given-names></name> and <name><surname>Kirkwood</surname><given-names>T. B.</given-names></name>
<article-title>Accumulation of defective mitochondria through delayed degradation of damaged organelles and its possible role in the ageing of post-mitotic and dividing cells</article-title>. <source><italic toggle="yes">Journal of theoretical biology</italic></source>
<volume>202</volume>(<issue>2</issue>), <fpage>145</fpage>&#x02013;<lpage>160</lpage> (<year>2000</year>). <pub-id pub-id-type="doi">10.1006/jtbi.1999.1046</pub-id>
<?supplied-pmid 10640434?><pub-id pub-id-type="pmid">10640434</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref090"><label>90</label><mixed-citation publication-type="journal">
<name><surname>Twig</surname><given-names>G.</given-names></name>, <name><surname>Elorza</surname><given-names>A.</given-names></name>, <name><surname>Molina</surname><given-names>A. J.</given-names></name>, <name><surname>Mohamed</surname><given-names>H.</given-names></name>, <name><surname>Wikstrom</surname><given-names>J. D.</given-names></name>, <name><surname>Walzer</surname><given-names>G.</given-names></name>, <name><surname>Stiles</surname><given-names>L.</given-names></name>, <name><surname>Haigh</surname><given-names>S. E.</given-names></name>, <name><surname>Katz</surname><given-names>S.</given-names></name>, <name><surname>Las</surname><given-names>G.</given-names></name>, <etal>et al</etal>
<article-title>Fission and selective fusion govern mitochondrial segregation and elimination by autophagy</article-title>. <source><italic toggle="yes">The EMBO journal</italic></source>
<volume>27</volume>(<issue>2</issue>), <fpage>433</fpage>&#x02013;<lpage>446</lpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1038/sj.emboj.7601963</pub-id>
<?supplied-pmid 18200046?><pub-id pub-id-type="pmid">18200046</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref091"><label>91</label><mixed-citation publication-type="journal">
<name><surname>Busch</surname><given-names>K. B.</given-names></name>, <name><surname>Kowald</surname><given-names>A.</given-names></name>, and <name><surname>Spelbrink</surname><given-names>J. N.</given-names></name>
<article-title>Quality matters: how does mitochondrial network dynamics and quality control impact on mtDNA integrity?</article-title>
<source><italic toggle="yes">Philosophical Transactions of the Royal Society B: Biological Sciences</italic></source>
<volume>369</volume> (<issue>1646</issue>), <fpage>20130442</fpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1098/rstb.2013.0442</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref092"><label>92</label><mixed-citation publication-type="journal">
<name><surname>Poovathingal</surname><given-names>S. K.</given-names></name>, <name><surname>Gruber</surname><given-names>J.</given-names></name>, <name><surname>Halliwell</surname><given-names>B.</given-names></name>, and <name><surname>Gunawan</surname><given-names>R</given-names></name>. <article-title>Stochastic drift in mitochondrial DNA point mutations: a novel perspective ex silico</article-title>. <source><italic toggle="yes">PLoS computational biology</italic></source>
<volume>5</volume>(<issue>11</issue>), <fpage>e1000572</fpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000572</pub-id>
<?supplied-pmid 19936024?><pub-id pub-id-type="pmid">19936024</pub-id></mixed-citation></ref><ref id="pcbi.1007023.ref093"><label>93</label><mixed-citation publication-type="book">
<name><surname>Johnston</surname><given-names>I. G.</given-names></name> and <name><surname>Jones</surname><given-names>N. S.</given-names></name>
<chapter-title>Closed-form stochastic solutions for non-equilibrium dynamics and inheritance of cellular components over many cell divisions</chapter-title> In <source><italic toggle="yes">Proc. R. Soc. A</italic></source>, <volume>volume 471</volume>, <fpage>20150050</fpage>
<publisher-name>The Royal Society</publisher-name>, (<year>2015</year>).</mixed-citation></ref><ref id="pcbi.1007023.ref094"><label>94</label><mixed-citation publication-type="journal">
<name><surname>Salvatier</surname><given-names>J.</given-names></name>, <name><surname>Wiecki</surname><given-names>T. V.</given-names></name>, and <name><surname>Fonnesbeck</surname><given-names>C</given-names></name>. <article-title>Probabilistic programming in python using pymc3</article-title>. <source><italic toggle="yes">PeerJ Computer Science</italic></source>
<volume>2</volume>, <fpage>e55</fpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.7717/peerj-cs.55</pub-id></mixed-citation></ref></ref-list></back></article>